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Abstract 
Ghrelin is a 28 amino acid peptide hormone that is acylated on the third amino acid 
residue of serine. The ghrelin axis, comprising ghrelin and its receptor, is expressed by 
cells of the bone and cartilage microenvironments indicating that it may modulate 
skeletal metabolism. Positive correlations have been observed between ghrelin levels 
and bone mineral density (BMD) in several human populations, and administration of 
ghrelin increases BMD in rodents. Ghrelin receptor (GHSR1a) knockout (GHSR-/-) mice 
have shown significantly weaker bone micro-architectures with ageing due to increased 
osteoclast activity. As GHSR1a only partly mediates acyl ghrelin signalling, the first part 
of this project aimed to characterise the bone microarchitecture of adult GOAT-/- mice, 
which do not produce the acylated form of ghrelin. Micro-computed tomography (micro-
CT) was used to evaluate the trabecular and cortical bone micro-architecture of the 
femora and tibiae of female GOAT-/- mice and wildtype (WT) control mice aged 6, 9 and 
18 months. The results showed that the trabecular bone microarchitecture of GOAT-/- 
mice aged 6 months had significantly less (p<0.05) bone volume fraction (BV/TV) as a 
result of decreased (p<0.05) trabecular connectivity, indicating that acyl ghrelin is 
involved in the regulation of physiological bone remodelling, by affecting the 
microarchitecture of trabecular bone. The trabecular BMD was not significantly different 
(p>0.05) in the GOAT-/- mice, indicating that acyl ghrelin signalling contributes to 
maintaining bone strength by affecting the microstructural property of trabecular bone 
rather than the mineralisation of the trabecular bone of adult mice. Reduced connectivity 
density may be a result of increased osteoclast activity due to the lack of acyl ghrelin 
signalling as reported with GHSR-/- mice. Trabecular BMD and BV/TV were not 
significantly (p>0.05)  different in the 9 and 18 month old GOAT-/- mice compared to 
WT, however, the GOAT-/- mice at these ages were significantly heavier, and therefore 
the results may have been compromised. The cortical bone compartment of the GOAT-/- 
mice demonstrated distinctly different regulatory patterns to the trabecular bone 
compartment. Cortical BMD of the femora and tibiae of 6 month old GOAT-/- mice was 
significantly greater (p≤0.05) than the WT controls, indicating that lack of acyl ghrelin 
signalling improves mineralisation. The resistance of cortical bone in the mid-diaphyses 
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(pMOI) of the femora of GOAT-/- mice at 6 months was not significantly different 
(p>0.05) compared to WT controls, however, the tibiae showed significantly reduced 
pMOI compared to WT controls. The periosteal apposition was not affected in the 
absence of acyl ghrelin as indicated by the lack of difference (p<0.05) in the GOAT-/- 
mouse femora and tibiae compared to WT controls. The endosteal resorption was 
reduced as the endosteal perimeter showed a significantly reduced (p<0.05) endosteal 
perimeter in the femora and tibiae of GOAT-/- mice. This suggests that osteoclast activity 
may be reduced in the cortical compartment of GOAT-/-, unlike the trabecular 
compartment which suggested that the osteoclast activity enhanced in the GOAT-/- 
mice.  
Rat chondrocytes and human immortalised chondrocytes have been shown to express 
ghrelin, but lack GHSR1a. In the second part of this project, we investigated whether 
ghrelin and GHSR1a is expressed by chondrocytes of the first trimester human fetal 
skeleton and mouse embryos and fetuses by immunohistochemistry. Ghrelin 
immunoreactivity was not seen in the chondrocytes of the first trimester human fetal 
upper limbs, lower limbs and vertebrae, suggesting that an autocrine/ paracrine ghrelin 
signalling pathway may be absent in the cartilage microenvironment. GHSR1a 
immunoreactivity was observed in the chondrocytes of the first trimester human fetal 
upper limbs, lower limbs and vertebrae, and mouse embryos/ fetuses aged E14.5, 
E16.5 and E18.5. Immunoreactivity was seen in the proliferating and mature 
hypertrophic chondrocytes identified based on morphology. Furthermore, ghrelin is 
associated with GH release and GH signals through GHR. GHR has been reported to 
be expressed by second trimester human fetal chondrocytes. Therefore, we further 
investigated, by immunohistochemistry whether GHR is expressed by chondrocytes of 
first trimester human fetal tissues and mouse embryos/ fetuses. GHR immunoreactivity 
was not observed in the chondrocytes of the first trimester human fetal chondrocytes, 
however, chondrocytes of E14.5, E16.5 and E18.5 mouse embryos/fetuses showed 
immunoreactivity. This project has shown that the ghrelin axis has a role in the 
regulation of the bone and cartilage microenvironments. Further work is necessary to 
determine whether the role in bone is direct (independent of other hormones such as 
GH) and whether pharmacological applications such as ghrelin mimetics have the 
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potential to improve the bone microarchitecture in models of bone loss. Further work on 
determining expression of GHSR1a and GHR in chondrocytes based on the stages of 
endochondral ossification between the human and mouse embryos/fetuses will provide 
knowledge of the GHR and GHSR1a signalling commencement during skeletal 
development. 
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Chapter 1 
 
General Introduction 
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1.1 Bone Structure and Function 
 
Bone diseases represent a major health and economic burden for society with 
increasing demand for effective therapies. Some of these diseases include 
osteoporosis, Paget’s disease of bone, rickets, osteomalacia and osteogenesis 
imperfecta (Bone Health and Osteoporosis: A Report of the Surgeon General, 2004). 
Osteoporosis is a major metabolic bone disease and is estimated to affect 200 million 
women worldwide and 75 million people in Europe, USA and Japan (International 
Osteoporosis Foundation, 2013). The annual treatment cost for osteoporotic fractures in 
the workplace in the USA, Canada and Europe is almost US$48 billion (International 
Osteoporosis Foundation, 2013). The regulation of the bone microenvironment is under 
the influence of environmental, mechanical and endogenous chemical activity. 
Understanding the physiology of the regulation of the bone microenvironment by 
endogenous chemicals (hormones, growth factors and cytokines) may lead to progress 
in effective therapeutic and management strategies for metabolic bone diseases. 
 
Bone is a complex, metabolically dynamic, specialised connective tissue which is 
composed of cells and extracellular matrix, like all connective tissues. The extracellular 
matrix of bone is made up of organic components (~ 30%), such as collagenous fibres, 
(90% of which is type I collagen), proteoglycans, glycosaminoglycans, glycoproteins, 
osteonectin (which anchors bone mineral to collagen) and osteocalcin (Clarke, 2008; 
Gentili & Cancedda, 2009). Almost 70% of bone is inorganic material which is mainly 
composed of the bone mineral composite, hydroxyapatite (Ca5[PO4]3[OH]), which is the 
storage form of calcium and phosphate (Clarke, 2008). The main types of cells in bone 
tissue are osteoblasts, which produce the organic matrix (osteoid), osteoclasts, which 
break down bone tissue (bone resorption), and osteocytes which act as 
mechanosensory and endocrine cells (Crockett, Rogers, Coxon, Hocking, & Helfrich, 
2011). Macroscopically, there are two types of bone tissue: the cortical bone, which 
constitutes approximately 80% of the skeleton and the trabecular bone (which 
comprises ~20% of skeleton). Cortical bone is dense and solid, consisting of compact 
collagenous fibres positioned in concentric sheets, or lamellae which run in 
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perpendicular planes around osteons containing blood vessels and nerves in a central 
canal (Clarke, 2008). Trabecular bone is composed of a honeycomb-like network of 
bony plates or rods interspersed in the bone marrow compartment (Clarke, 2008).  
 
Bone tissue functions to provide structural support, permit movement and locomotion by 
providing levers for muscles, to protect vital internal organs, provide maintenance of 
mineral homeostasis and acid-base balance, serve as a reservoir of growth factors and 
cytokines, and provide the environment for haematopoiesis within the marrow spaces 
(Chappard, Baslé, Legrand, & Audran, 2008; Taichman, 2005). Based on size, bones 
can be classified as long, short, flat or irregular bones. Short bones are cuboidal in 
shape and many examples are located in the foot (tarsals) and wrist (carpals) (Kulkarni, 
2012). Long bones are tubular in shape with a hollow shaft and two ends and are 
located in the upper and lower limbs. The gross structure of long bones consists of two 
main regions: the epiphyses (often paired)and diaphysis (Figure 1.1-1). The diaphysis is 
the main shaft of the long bone, composed mainly of cortical bone, where it provides 
strength and high resistance to bending and torsion. The epiphyses are the upper and 
lower ends of long bones. The funnel-shaped regions of the diaphysis closest to the 
epiphyses at both ends is referred to as the metaphyses. The epiphyses and 
metaphyses are composed of a thin layer of cortical bone tissue, encapsulating a dense 
trabecular bone network.  
 
The trabeculae follow lines of stress changes and realign in the direction of stress to 
attenuate the compressive forces and help the bone maintain its shape (Clarke, 2008; 
Feng & McDonald, 2011& Premkumar, 2011). In 1892, Wolff found that the orientation 
of trabeculae coincides with the direction of stress trajectories and proposed that bone 
loading is sensed in the bone microenvironment and that bone adapts its structure 
accordingly. This principle of functional adaptation is known as Wolff’s Law (Altenbach, 
2013). It occurs in conditions of disuse, such as during immobility, space flight and long 
term bed rest, when bone is lost, and in overloading such as increased exercise 
regimes, which causes a gain in bone mass (Altenbach, 2013). It also occurs in growth, 
when the refined trabecular bone in childhood is changed to a coarser trabecular 
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morphology in maturity (Altenbach, 2013), after fracture healing and in relation to 
orthopaedic implant incorporation (Altenbach, 2013). 
 
 
Figure 1.1-1: Typical structure of a long bone showing the epiphyses, metaphyses and 
diaphysis (Adapted from 
http://www.bbc.co.uk/schools/gcsebitesize/pe/appliedanatomy/2anato my_skeleton _ 
rev4.shtml).  
 
 
1.2 Bone modelling and remodelling 
 
Bone continuously adapts to physiological influences (including hormones, growth 
factors and cytokines) and environmental influences (such as mechanical strains) (Feng 
& McDonald, 2011; Kini & Nandeesh, 2012). The ability of bone to adapt to mechanical 
load is brought about by continuous cycles of bone resorption and bone formation 
activity. If these processes occur at different locations, by the uncoupled independent 
actions of osteoclasts and osteoblasts, the bone morphology (structure, size and shape) 
is altered in order to maintain its mechanical integrity, and this process is known as 
bone modelling (Frost, 1990a). During growth bone modelling is the predominant 
process which affects the size and shape of bones, especially in long bones as they 
grow in length (Brandi, 2009). Modelling also occurs throughout life in response to 
changing mechanical loads, and particularly in the cortical bone of the mid-shaft of long 
Metaphysis 
Metaphysis 
Trabecular bone Cortical bone 
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bones (Burr & Allen, 2014; Brandi 2009). In the late 1980s, Frost proposed a conceptual 
model, which he called the mechanostat theory to mathematically explain bone 
adaptation to mechanical signals. He proposed that the strain magnitude is a 
mechanical stimulus for bone functional adaptation. Strain is the relative change in 
length of bone, or deformation of bone tissue that occurs with loading (Burr & Allen, 
2014; Frost 1990). The mechanostat theory has been further modified to include more 
strain-related characteristics which stimulates bone functional adaptation such as strain 
rate, the frequency of loading cycles, the amount of rest between loading cycles and 
bouts of loading, and the distribution of strain within the bone structure (Skerry, 2006).  
 
In addition to bone modelling, bone remodelling serves to maintain bone strength and 
mineral homeostasis by the coupled action of osteoclasts and osteoblasts. Remodelling 
occurs firstly through resorption of bone by osteoclasts, followed by formation of bone 
by osteoblasts in a tightly coupled manner, so that the net effect maintains bone 
strength and mineral homeostasis (Burr & Allen, 2014). The remodelling process 
consists of four major distinct phases; activation, resorption, reversal and formation 
(Figure 1.2-1). Remodelling sites may develop randomly, but many sites are targeted to 
areas that require repair (Clarke, 2008). Activation involves the recruitment and 
activation of mononuclear monocyte-macrophage osteoclast precursors from the 
circulation to the bone surface (Bruzzaniti & Baron, 2006). This leads to the 
differentiation, migration and fusion of the large multinucleated osteoclasts to the 
mineralised bone surface to initiate resorption (Clarke, 2008; Kini & Nandeesh, 2012; 
Parra-Torres, Valdés-Flores, Orozco, & Velázquez-Cruz, 2013). During the resorption 
phase, osteoclasts break down the matrix at the attached interface between the 
osteoclasts and bone, resulting in resorption pits  (Crockett et al., 2011; Seeman, 2009). 
The release of growth factors contained within the matrix and by osteocytes results in 
the recruitment of mesenchymal stem cells and osteoprogenitor cells to the resorption 
pits (Figure 1.2-1) (Crockett et al., 2011; Feng & McDonald, 2011). The reversal and 
formation phases involve the proliferation and differentiation of osteoprogenitor cells into 
osteoblasts. Osteoblasts then deposit unmineralised bone matrix (osteoid) onto the 
surface of the cavities, and differentiate further into osteocytes which then reside in 
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lacunae in the matrix. The osteoid becomes mineralised to complete the remodelling 
cycle (Figure 1.2-1) (Crockett et al., 2011; Feng & McDonald, 2011; Parra-Torres et al., 
2013; Seeman, 2009).  
 
 
Figure 1.2-1: The bone remodelling process. The remodelling process consists of four 
major distinct phases: Phase 1: activation of bone remodelling at a specific site from the 
resting state, Phase 2: bone resorption by osteoclasts, Phase 3: reversal phase in 
which osteoclast activity halts and osteoblast activity begins, Phase 4: formation of bone 
by osteoblasts (Adapted from Sebba, 2013). 
 
In normal bone remodelling, there is no net change in bone mass and strength after 
each remodelling cycle due to temporal and spatial alignment of osteoclast and 
osteoblast activity (Feng & McDonald, 2011). Any disturbance to this tightly regulated 
system causes an uncoupling of the activity of osteoclasts and osteoblasts and results 
in either significant bone loss or more rarely an increase in bone mass. With increasing 
age, the rate of the formation phase for bone renewal is unable to compensate for the 
increased activity of osteoclasts in the resorption phase. This results in decreased bone 
mass and an alteration of the micro-architecture, which results in decreased bone 
strength, increased bone fragility and increased risk of fracture (Parfitt, 1984; Seeman, 
Activation 
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2013). These features are typical of age-related metabolic bone disease such as 
osteoporosis (Chen, Zhou, Fujita, Onozuka, & Kubo, 2013; Seeman, 2013).  
 
Bone strength is determined by bone geometry, cortical thickness and porosity, 
trabecular bone morphology, and intrinsic material properties of bone tissue, such as 
mineralisation (Ammann & Rizzoli, 2003). Changes in microarchitecture with increasing 
age are reflected in trabecular bone through the decline in the bone volume fraction, 
trabecular number, connectivity density and trabecular thickness, and an increase in 
trabecular separation (defined in Table 1.2-1), although the degree of change is site-
specific (Parkinson & Fazzalari, 2013). Furthermore, the cortical bone of the diaphysis 
of long bones undergoes significant age-related changes, including a decrease in 
cortical thickness (Chen et al., 2013; Parfitt, 1984) and increases in periosteal (outer) 
and endosteal (inner) circumferences (Clarke, 2008). This results in altered geometric 
properties, including changes in the area moment of inertia and polar moment of inertia. 
The area and polar moments of inertia are the distribution of bone tissue around the 
axis of bending and torsion, respectively, and they indicate the bone’s resistance to 
bending/torsion and the ability to resist fracture under these conditions (Brandi, 2009).      
 
Table 1.2-1: Definition of three dimensional trabecular bone microarchitectural indices 
as measured in computed tomography (adapted from Bouxsein et al., 2010). 
Indices Definition 
Bone volume fraction Ratio of the bone tissue volume to the total tissue volume of 
the region of interest 
Trabecular number Measure of the average number of trabeculae per unit length 
normalised by tissue volume 
Trabecular thickness Mean thickness of trabeculae 
Trabecular separation Mean distance between trabeculae 
Connectivity density Measure of the degree of connectivity of trabeculae 
 
The metabolic activity of osteoblasts, osteoclasts and osteocytes is regulated by 
mechanical strain and a complex network of endogenous chemicals (hormones, growth 
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factors, cytokines and neurotransmitters) for bone modelling and remodelling to 
maintain skeletal integrity. Examples of these endogenous chemicals include growth 
hormone (GH), insulin like growth factor-I (IGF-I), oestrogen, parathyroid hormone, 
1,25-dihydroxy vitamin D, thyroid hormone, bone morphogenetic proteins (BMPs), 
prostaglandins and calcitonin (Oxlund, Ejersted, Andreassen, Torring, & Nilsson, 1993; 
Parra-Torres et al., 2013; Raisz, 1999). Emerging evidence suggests that the peptide 
hormone ghrelin may also be a key endogenous factor involved in regulating bone 
metabolism (P. J. D. Delhanty, van der Eerden, & van Leeuwen, 2013).  
 
1.3 Osteogenesis and chondrogenesis 
 
There are two distinct mechanisms of bone formation, or osteogenesis; 
intramembranous ossification and endochondral ossification (Olsen, Reginato, & Wang, 
2000). Intramembranous ossification mainly occurs during the development of the flat 
bones of the skull, the mandible, maxillae and clavicles. It is also an essential process in 
appositional bone growth at the periosteum and the process of bone repair in the 
healing of bone fractures. It begins through the development of a fibrous membrane 
which is derived from the differentiation of mesenchymal stem cells into osteoprogenitor 
cells. The osteoprogenitor cells then differentiate further into osteoblasts and this leads 
to the formation of new bone tissue (Clarke, 2008).  
 
Endochondral ossification mainly occurs during the development of the vertebral 
column, pelvis and bones of the upper and lower limbs and during postnatal longitudinal 
growth at the epiphyseal growth plates. It is also involved in the healing of fractures at 
sites of high mobility and/or poor vascularisation following trauma. During development, 
endochondral ossification involves the initial formation of a cartilage template 
(chondrogenesis) by the condensation and differentiation of mesenchymal stem cells 
into chondroblasts (Clarke, 2008; Mackie, Ahmed, Tatarczuch, Chen, & Mirams, 2008). 
The cartilage template consists of morphologically distinct chondrocytes which rest, 
proliferate, mature (hypertrophy) and undergo apoptosis. Chondrocytes undergoing 
 
 
9 
 
hypertrophy secrete angiogenic factors such as vascular endothelial growth factors 
(VEGF), to induce vascular invasion of the cartilage-template to allow delivery of 
osteoprogenitor cells and the subsequent formation of ossification centres. This results 
in the gradual replacement of the cartilage template with newly formed bone (Mackie, 
Tatarczuch, & Mirams, 2011). Chondrogenesis and endochondral ossification are 
controlled exquisitely by cellular interactions, growth and differentiation factors, and 
other environmental factors that initiate or suppress cellular signalling pathways and the 
transcription of specific genes in a temporo-spatial manner (Tuan, 2004). Endogenous 
mediators, such as growth hormone, IGF-I, thyroid hormone, parathyroid hormone, 
bone morphogenetic proteins and fibroblast growth factors are involved in the regulation 
of chondrogenesis and endochondral ossification (Mackie et al., 2008; Stevens & 
Williams, 1999) and there is growing evidence that the ghrelin axis plays an important 
role in chondrogenesis and possibly endochondral ossification (Caminos et al., 2005; 
Gomez, Lago, Gomez-Reino, Dieguez, & Gualillo, 2009; Nakahara et al., 2006).  
 
 
1.4 Growth hormone in bone remodelling and cartilage metabolism  
 
Growth hormone is a 191 amino acid hormone which is secreted in a pulsatile pattern 
from the anterior pituitary in response to regulatory hormones such as growth hormone 
releasing hormone (GHRH), somatostatin and ghrelin. It functions by signalling through 
the growth hormone receptor (GHR) and it has a role as an anabolic regulator of energy 
metabolism and growth (DiGirolamo et al., 2007). GH plays an important role in bone 
remodelling, stimulating bone formation and bone resorption. GH regulates remodelling 
directly by binding to GHR on osteoblasts and osteoclasts, and indirectly by stimulating 
IGF-I release, which in turn regulates cellular activity in bone. GH stimulates osteoblast 
proliferation and activity, stimulating bone formation. GH also stimulates osteoclast 
differentiation to regulate bone resorption (Chihara & Sugimoto, 1997). 
 
GH deficiency in children and adults affects skeletal mineralisation (Drake, Howell, 
Monson, & Shalet, 2001; Litwack, 2008; Root & Root, 2002). GH treatment initially 
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increases bone resorption, leading to an increase in bone remodelling sites, with the 
subsequent stimulation of bone formation (Gotherstrom et al., 2001; Koranyi et al., 
2001; Litwack, 2008; Ohlsson, Bengtsson, Isaksson, Andreassen, & Slootweg, 1998). 
This leads to a net increase in bone mass, but only when GH treatment is continued for 
a prolonged period (Gotherstrom et al., 2001; Koranyi et al., 2001; Litwack, 2008; 
Ohlsson et al., 1998). This is known as the biphasic model of growth hormone action on 
bone. The results of studies in non-GH deficient osteoporotic patients treated with GH 
are contradictory. GH has a positive effect on bone mass in postmenopausal women 
(Landin-Wilhelmsen, Nilsson, Bosaeus, & Bengtsson, 2003; Litwack, 2008) and in men 
with idiopathic osteoporosis, but in another study a decrease in bone mineral density 
(BMD) was reported (Gillberg, Mallmin, Petrén-Mallmin, Ljunghall, & Nilsson, 2002). 
The potential therapeutic benefits of GH are dependent on the dose, frequency and 
duration of the treatment (Litwack, 2008). Treatment with GH secretagogues, which 
stimulate GH release, could provide a more successful therapeutic approach (Litwack, 
2008). Ghrelin, the endogenous GH secretagogue, has also been investigated for its 
therapeutic potential as a growth hormone releasing agent (Arvat et al., 2001).   
 
Studies on growth hormone receptor (GHR) expression have been performed during 
chondrogenesis using human fetal tissues (Werther, Haynes, Edmonson, et al., 1993; 
Werther, Haynes, & Waters, 1993; Werther, Haynes, Barnard, & Waters, 1990). These 
studies showed that GHR is expressed by chondrocytes of the developing sternum and 
costal cartilages of human fetuses aged 15-20 weeks (Werther, Haynes, & Waters, 
1993; Werther et al., 1990) and infants aged 3 days to 8 months (Werther, Haynes, & 
Waters, 1993). This indicates that growth hormone signalling may regulate the 
embryological development of the skeleton through endochondral ossification. It is 
possible that the GHR could be targeted for the treatment of endochondral skeletal 
abnormalities such as skeletal dysplasias. There have not, however, been any reports 
describing the expression of GHR receptors on other chondrogenic sites such as limbs 
or vertebrae. Studying the expression of GHR would determine whether the expression 
patterns are site- or cell type dependent.   
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1.5 The ghrelin axis 
 
Ghrelin is a pleiotropic 28 amino acid peptide hormone (Kojima et al., 1999) which has 
roles in Gh release release (Kojima et al., 1999), appetite regulation (Wren et al., 2000) 
and energy balance (Kirchner, Heppner, & Tschop, 2012); and it has been 
demonstrated to play roles in bone metabolism and formation (Amini et al., 2013; Choi 
et al., 2013; P. J. Delhanty et al., 2006; P. J. D. Delhanty et al., 2013; Deng, Ling, Ma, 
Liu, & Zhang, 2008), and cartilage metabolism (Caminos et al., 2005; Gomez et al., 
2009). Emerging evidence indicates that ghrelin signalling has a potential anabolic 
regulatory role in bone homeostasis through the dual regulation of osteoblasts and 
osteoclasts (Choi et al., 2013; Costa et al., 2011; Fukushima et al., 2005; van der Velde 
et al., 2012). Ghrelin signalling also improves bone tissue healing through 
intramembranous ossification (Deng et al., 2008) and has been shown to be involved in 
the regulation of chondrocyte metabolism (Caminos et al., 2005), suggesting that it 
could also have regulatory roles in endochondral ossification. Thus, an understanding of 
ghrelin physiology has the potential to offer new therapeutic strategies for metabolic 
diseases of bone and cartilage. 
  
The ghrelin gene (GHRL) is located on the chromosomal locus 3p25.6-3p26.2 and 
encodes the 117 amino acid preproghrelin peptide (Kang, Zmuda, & Sleeman, 2011; 
Kojima et al., 1999; Kojima & Kangawa, 2005). Preproghrelin gives rise to a number of 
products through alternative splicing and post-transcriptional processing. The N-
terminal, 23 amino acid signal peptide is cleaved to leave a 94 amino acid segment 
termed proghrelin (Fig 1.5-2). Proghrelin is cleaved further by prohormone convertases 
(PC) 1/3, furin and PC2 (Takahashi et al., 2009; Zhu, Cao, Voogd, & Steiner, 2006) to 
give rise to the 28 amino acid ghrelin and a 66 amino acid C-terminal peptide termed C-
ghrelin (Fig 1.5-2). C-ghrelin gives rise to a 23 amino acid peptide hormone, obestatin 
(B. Liu, Garcia, & Korbonits, 2011; Zhang et al., 2005). Both C-ghrelin and obestatin are 
present in the circulation, with obestatin circulating at lower concentrations than ghrelin, 
while C-ghrelin circulates at higher concentrations (Bang, Soule, Yandle, Richards, & 
Pemberton, 2007; Mondal, Toshinai, Ueno, Koshinaka, & Nakazato, 2008; Pemberton, 
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Wimalasena, Yandle, Soule, & Richards, 2003). Ghrelin circulates as a post-
translationally modified form, acyl ghrelin, and an unacylated form, desacyl ghrelin 
(Hosoda, Kojima, Matsuo, & Kangawa, 2000). Desacyl ghrelin is present in the 
circulation in higher concentrations than acyl ghrelin and represents approximately 80% 
of total circulating ghrelin (Date et al., 2000; Hosoda et al., 2000). The addition of the 
octanoyl group to the serine-3 residue of proghrelin by the enzyme ghrelin O-acyl 
transferase (GOAT) produces acyl ghrelin (Gutierrez et al., 2008; Yang, Brown, Liang, 
Grishin, & Goldstein, 2008). GOAT is a member of the membrane-bound O-
acyltransferase (MBOAT) superfamily and is encoded by the MBOAT4 gene (Gutierrez 
et al., 2008; Yang et al., 2008). GOAT octanoylates serine-3 of proghrelin in the 
endoplasmic reticulum lumen and can use a range of fatty acid substrates, with the 
most likely acyl donors being acyl-CoAs (Al Massadi, Tschop, & Tong, 2011; Gahete et 
al., 2014; Nishi et al., 2005).   
 
The action of acyl ghrelin, including the stimulation of growth hormone release, is 
mediated largely through the growth hormone secretagogue receptor 1a (GHSR1a) 
(Howard et al., 1996; Kojima et al., 1999), although an additional, alternative ghrelin 
receptor is widely hypothesised (Caminos et al., 2005; Muccioli et al., 2004; Thielemans 
et al., 2007; Volante et al., 2003). The GHS-R1a is a 366 amino acid G protein-coupled 
receptor (GPCR) with the characteristic seven transmembrane-spanning domains 
(Howard et al., 1996). The GHSR gene is located on chromosome 3q26.31 (Howard et 
al., 1996) and is transcribed into two GHSR mRNA isoforms, GHSR1a and GHSR1b 
(Chan & Cheng, 2004; McKee et al., 1997). GHSR1b is a 5 transmembrane, truncated 
protein and is widely considered to be non-functional, although there is evidence that it 
modifies GHSR1a trafficking and signalling (Chow et al., 2012; Leung et al., 2007). 
GHSR1a forms heterodimers with GHSR1b within the endoplasmic reticulum and this 
has a dominant-negative effect on ghrelin receptor function (Chow et al., 2012; Leung et 
al., 2007).  
 
 
 
13 
 
                     
                  
                                        
 
                                                       
Figure 1.5-1: The ghrelin axis includes the two major circulating forms of ghrelin, 
desacyl and acyl ghrelin, GOAT and the GHSR1a. Acyl ghrelin is formed by the post-
translational esterification of n-octanoyl group to the Ser-3 residue of the peptide by the 
enzyme GOAT. Acyl ghrelin signals through GHSR1a, however, both desacyl ghrelin 
and acyl ghrelin can signal through unknown receptors. (Adapted from Romero et al., 
2010). 
N-terminal peptide- (23)  
C-terminal peptide-(66)  
Obestatin- (23)  
Furin, PC1 /3 and PC2 
Furin, PC1 /3 
and PC2 
/(s) 
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The GHSR1a exhibits unusually high constitutive activity, as it signals with ~50% of its 
maximal capacity in the absence of acyl ghrelin (Holst, Cygankiewicz, Jensen, 
Ankersen, & Schwartz, 2003). Ghrelin acts through the GHSR1a to have many 
regulatory effects on physiology and behaviour, such as the mediation of growth 
hormone release (Arvat et al., 2000; Kojima et al., 1999), regulation of appetite and 
secretion of gastric acid and gut motility, the regulation of cell proliferation, apoptosis, 
bone homeostasis, fat accumulation, the enhancement of memory and learning, 
neuroprotection, immune function, blood glucose control, potentiation of drug and food 
addiction, and cardiovascular and renal protection (Arvat et al., 2000; Chopin et al., 
2011; P. J. D. Delhanty et al., 2013; Gahete et al., 2014; Jeffery, Herington, & Chopin, 
2003; Kishimoto, Tokudome, Hosoda, Miyazato, & Kangawa, 2012; Kojima et al., 1999; 
Sato et al., 2011; Skibicka, Hansson, Egecioglu, & Dickson, 2012; Takeda et al., 2006; 
Tschop, Smiley, & Heiman, 2000). 
 
Ghrelin also has functions in cells that do not express GHSR1a, and it stimulates 
proliferation and signalling in the human erythroleukaemic cell line (HEL) and HepG2 
cell line, which lack GHSR1a expression (Muccioli et al., 2004; Thielemans et al., 2007). 
Non-GHSR1a ghrelin binding sites have been demonstrated in many tissues including 
cartilage (Caminos, et al., 2005), normal thyroid glands, thyroid tumours and thyroid 
cancer cell lines (Volante et al., 2003), indicating the presence of an alternative receptor 
or receptors for acyl ghrelin. Desacyl ghrelin does not bind with a high affinity to 
GHSR1a, but has many important physiological effects such as the regulation of 
proliferation, apoptosis, appetite, adipogenesis and cardioprotective effects (P. J. 
Delhanty et al., 2006; Granata et al., 2007; Seim, Josh, Cunningham, Herington, & 
Chopin, 2011). This property of desacyl ghrelin suggests that unidentified receptors are 
present through which both desacyl ghrelin and acyl ghrelin signal.  
Ghrelin, GHSR1a and GOAT are expressed by a wide variety of tissues (Table 1.5-1). 
Ghrelin and GOAT are most abundantly expressed in the stomach (Date et al., 2000; 
Sakata et al., 2009) and GHSR1a is abundantly expressed by the somatotroph pituitary 
cells of the anterior pituitary gland (Litwack, 2007).  
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Table 1.5-1. Ghrelin, GOAT and GHSR1a mRNA and protein are expressed in human, 
mice and rat tissues, including bone and cartilage;  -expression has been documented 
and U- expression uncertain (Chopin et al., 2011; Date et al., 2000; Kojima & Kangawa, 
2005; Lim, Kola, Grossman, & Korbonits, 2011; Lim, Kola, & Korbonits, 2011; Sun, 
Garcia, & Smith, 2007) 
Tissue Ghrelin GHSR1a GOAT 
mRNA Protein mRNA Protein mRNA Protein 
Bone            U 
Cartilage            U       U   U 
Small & large 
intestine 
          U 
Pituitary & 
hypothalamus 
          U 
Adrenal gland            U 
Thyroid           U 
Pancreas            
Adipose tissue           U 
Stomach            
Brain           U 
Heart            U 
Kidney           U 
Liver           U 
Lung           U 
Lymph node           U 
Prostate & Testes            
Spleen & Thymus            U 
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1.5.1 The ghrelin axis in bone 
 
Ghrelin has been reported to have both direct and indirect effects on bone (Fukushima 
et al., 2005; van der Velde, Delhanty, van der Eerden, van der Lely, & van Leeuwen, 
2008). Ghrelin stimulates pituitary GH release synergistically with growth hormone 
releasing hormone (GHRH) (Kojima et al., 1999) and the GH axis may mediate some of 
the effects of the ghrelin axis in bone. GH enhances bone metabolism directly, by acting 
through the growth hormone receptor (GHR) and indirectly, by stimulating the release of 
insulin like growth factor-I (IGF-I), predominantly from the liver and also at the 
epiphyseal growth plate in cartilage and bone (Cannata, Vijayakumar, Fierz, & LeRoith, 
2010). GH and IGF-I are essential determinants of longitudinal bone growth, skeletal 
maturation and acquisition of bone mass and are important in maintaining bone mass 
and density by regulating bone modelling and remodelling (Cannata, Vijayakumar, 
Fierz, & LeRoith, 2010; Giustina, Mazziotti, & Canalis, 2008; Wit & Camacho-Hubner, 
2011).  
 
While the role of GH and IGF-I in bone is well established, there is also evidence that 
ghrelin has GH-independent effects on bone and cartilage. The intraperitoneal injection 
of ghrelin at a dose of 50µg/kg/day in GH deficient spontaneous dwarf rats for 4 weeks, 
for example, increased the bone mineral density of the cortical and trabecular bone of 
the femur (Fukushima et al., 2005), suggesting that ghrelin has a GH-independent role 
in bone metabolism.  
 
 
1.5.2 Expression of the ghrelin axis in bone, bone-derived cell lines and cartilage  
 
The ghrelin axis is expressed in bone and bone-derived cell lines, indicating that it may 
play a role in bone tissues. Human and rodent osteoblasts express ghrelin and 
GHSR1a (P. J. Delhanty et al., 2006; Fukushima et al., 2005; Kim et al., 2005; Liao L. & 
Wang, 2010; Maccarinelli et al., 2005). Ghrelin mRNA is expressed in human bone 
biopsies and in the SV-HFO human pre-osteoblastic cell line (P. J. Delhanty et al., 
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2006) and the TE-85 and MG-63 human osteosarcoma cell lines (Pacheco-Pantoja, 
Ranganath, Gallagher, Wilson, & Fraser, 2011). Ghrelin and GHSR1a mRNA and 
protein have been detected in cultured human osteoblasts (Liao L. & Wang, 2010) and 
the MG-63 and Sa-OS2 human osteosarcoma cell lines (Kim et al., 2005). Ghrelin and 
GHSR1a mRNA and protein are expressed in primary osteoblast-like cells cultured from 
21 day fetal rat calvaria (Fukushima et al., 2005; Maccarinelli et al., 2005), in the 
MC3T3-E1 primary mouse osteoblastic cell line, and the UMR-106 and ROS-17/2.8 rat 
osteosarcoma cell lines (Kim et al., 2005). Although expression has been described in 
osteoblasts in a number of studies, there have been few studies describing expression 
in osteoclasts. Ghrelin and GHSR1a mRNA transcript expression has been 
demonstrated in mouse osteoclasts, indicating a possible role in bone resorption (van 
der Velde et al., 2012).  
 
The ghrelin axis is also expressed in chondrocytes and may play a role in 
chondrogenesis. The ghrelin peptide and mRNA are expressed in human and rodent 
chondrocytes (Caminos et al., 2005). Immunoreactive ghrelin is mainly expressed in the 
proliferative and maturative zones of the epiphyseal growth plate (Caminos et al., 2005). 
Although GHSR1a, transcripts were not identified in this study by RT-PCR, studies 
demonstrating positive 125I ghrelin binding (Caminos et al., 2005) suggest that ghrelin 
may exert its effects in cartilage via alternative ghrelin receptors.  
 
 
1.5.3 Functional effects of the ghrelin axis in bone – in vitro studies 
 
Studies in vitro have shown that ghrelin administration increases bone formation by 
enhancing the differentiation, proliferation and activity of osteoblasts (Costa et al., 2011; 
P. J. Delhanty et al., 2006; Fukushima et al., 2005; Kim et al., 2005; Maccarinelli et al., 
2005). Exogenous ghrelin administration stimulates a dose-dependent increase in 
proliferation in human SV-HFO pre-osteoblastic cells (P. J. Delhanty et al., 2006), 
human primary osteoblasts (Costa et al., 2011), primary osteoblasts cultured from 21 
day rat calvariae (Fukushima et al., 2005; Maccarinelli et al., 2005) and in the MC3T3-
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E1 primary mouse osteoblast cell line (Kim et al., 2005). Ghrelin treatment increases 
differentiation of osteoblasts by the expression of osteoblast differentiation markers 
such as Runx2 and collagen type α1 in primary rat calvarial cells in vitro (Fukushima et 
al., 2005). Administration of ghrelin also increases osteoblast activity, and increases 
alkaline phosphatase and osteocalcin production (markers of osteoblast differentiation 
and matrix production) in primary mouse osteoblast MC3T3-E1 cells (Kim et al., 2005) 
and primary rat calvaria in vitro (Fukushima et al., 2005; Maccarinelli et al., 2005), 
indicating that ghrelin may play a role in the differentiation and proliferation of 
osteoblasts.  
 
In contrast to studies on the effect of ghrelin on osteoblasts, a few studies report the 
role of ghrelin in osteoclasts (which resorb bone). Rat osteoclasts isolated from the long 
bones of 1-2 day old rats and co-incubated with ghrelin in vitro on bovine bone slices 
induced an increase in bone resorption (Costa et al., 2011), suggesting a role of ghrelin 
in enhancing osteoclast activity. As ghrelin has been shown to regulate osteoblastic and 
osteoclastic cells, a dual regulatory role on bone formation and resorption is suggested 
(Costa et al., 2011). Also, osteoclastogenesis is increased in marrow derived osteoclast 
cultures of GHSR knockout mice at 3 month of age compared to the wildtype control 
mice (van der Velde et al., 2012). 
 
 
1.5.4 Functional effects of ghrelin in bone homeostasis– clinical and in vivo 
studies 
 
A number of studies have indicated that ghrelin has effects on bone mineral density 
(BMD) in human populations (Misra et al., 2005; Napoli et al., 2011; Nouh, Abd Elfattah, 
& Hassouna, 2012; Oh et al., 2005; Weiss, Langenberg, & Barrett-Connor, 2006). 
Ghrelin secretion predicts bone density independent of body composition, the GH-IGF-I 
axis, cortisol, or oestradiol status in healthy girls (Misra et al., 2005). A significant 
positive correlation was found between ghrelin and BMD at the vertebral column, hip 
and radius of perimenopausal and postmenopausal women compared to 
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premenopausal women (Nouh et al., 2012). Serum ghrelin was positively correlated with 
trabecular BMD of the tibia in a cohort of elderly healthy Italian women and correlated in 
men, however the latter did not reach statistical significance (Napoli et al., 2011). A 
beneficial association between circulating ghrelin concentration and bone density was 
found in women in the Newfoundland (a Canadian) population (Amini et al., 2013), with 
higher serum ghrelin concentrations correlated with higher bone density measurements 
in the vertebral column, femoral neck and hip. This association was independent of 
confounding factors including body mass index, physical activity, age, alcohol 
consumption and smoking (Amini et al., 2013) indicating that ghrelin plays a role in 
regulating bone homeostasis in vivo. In contrast, ghrelin levels are elevated in girls with 
anorexia nervosa, and ghrelin secretion does not predict bone density in the lumbar 
spine and hip, independent of body composition, the GH-IGF-I axis, cortisol, or 
oestradiol (Misra et al., 2005). In girls with Rett’s syndrome, serum ghrelin levels were 
significantly higher than in age matched healthy subjects, with no association between 
ghrelin levels and BMD (Caffarelli et al., 2012). This suggests that ghrelin levels are 
elevated in anorexia nervosa and Rett’s syndrome in a compensatory manner and 
patients with these conditions are likely to be ghrelin resistant.  
 
Serum ghrelin levels were not correlated with the BMD of the lumbar vertebrae and 
femoral neck of middle-aged males (Oh et al., 2005). Ghrelin also did not show an 
association with BMD or short-term change in BMD in older males and females (Weiss 
et al., 2006), however, ghrelin was inversely associated with the bone resorption marker 
N-terminal telopeptide of collagen (NTX) in males and positively associated with NTX in 
females, indicating that ghrelin plays a role in bone turnover (Weiss et al., 2006). This 
suggests that ghrelin may regulate bone metabolism differently in males compared to 
females.  
 
There are difficulties associated with the accurate measurement of plasma ghrelin 
levels, however, and accurate measurement is critically dependent on the protocols 
used in the preparation of samples and the assays. There are no international 
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standards for the measurement of ghrelin levels, and therefore, the results from different 
laboratories tend to vary widely depending on the protocols used (Chopin et al., 2012). 
 
Studies from GHSR knockout mice suggest that ghrelin signalling may play an 
important role in maintaining bone mass and micro-architecture with progressing age 
(van der Velde et al., 2012). Densitometry analysis of bone mineral density (BMD)  in 
ghrelin-null mice at 8 weeks of age (Sun, Ahmed, & Smith, 2003) and GHSR-null mice 
at 24 weeks of age (Sun, Wang, Zheng, & Smith, 2004) showed no change in bone 
mineral density compared to their wildtype littermates at the same ages. BMD is, 
however, a material property which partly contributes to bone strength, therefore, 
ghrelin signalling may affect the bone strength by affecting other material properties 
such as its organic or structural properties. Three dimensional (3D) micro-architectural 
analysis of the bone tissue through micro-CT would provide a more sensitive method for 
the analysis of the micro-structural effects on bone tissue in the knockout animals 
(D'Elia, Caracchini, Cavalli, & Innocenti, 2009). This method showed reduced trabecular 
bone volume fraction, trabecular number, cortical volume and polar moment of inertia 
on the femora of 6 month old GHSR knockout mice (van der Velde et al., 2012). There 
were no differences in these morphometric parameters at 3 months of age between the 
GHSR-/- and wild-type (WT) mice (van der Velde et al., 2012). This study indicates that 
ghrelin, signalling through GHSR1a, may play an important role in maintaining bone 
micro-architecture with progressing age through the regulation of the bone 
microenvironment (van der Velde et al., 2012). Furthermore, the osteoclast numbers on 
the bone surface of the 6 month old GHSR-/- mice were higher than the WT controls and 
no differences were observed in the 3 month old GHSR-/- mice compared to the WT 
controls, suggesting that a compensatory pathway is present at younger ages, which 
overrules the local stimulation of osteoclast activity (van der Velde et al., 2012). The 
bone formation marker, procollagen type 1 amino-terminal propeptide (P1NP), was 
unaltered in the GHSR-/- compared to WT (van der Velde et al., 2012). This indicates 
that the microarchitectural differences seen in GHSR-/- mice are mainly a result of 
altered osteoclast activity and not altered osteoblast activity, and therefore, the effects 
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of acyl ghrelin signalling may result from regulation of osteoclast activity more than 
osteoblast activity.   
 
Ghrelin (both acyl and desacyl forms) may also signal through hypothesised alternative 
receptors in bone in the absence of GHSR1a (Caminos et al., 2005; Muccioli et al., 
2004; Thielemans et al., 2007; Volante et al., 2003). Ghrelin signalling, therefore, may 
also occur in GHSR-/- mice through alternative receptors.  
 
As GHSR1a also possesses a high level of constitutive activity (Holst et al., 2003), the 
findings in the GHSR1a knockout mice (van der Velde et al., 2012) do not confirm that 
acyl ghrelin signalling through GHSR1a is solely responsible for the observed effects 
and further studies are required. Studies using GOAT-/- mice, which are unable to 
produce acyl ghrelin, would provide additional information on the relative contributions 
of acyl ghrelin, desacyl ghrelin and the GHSR1a and their role in maintaining bone 
micro-architecture with age. 
 
 
1.6 The role of the ghrelin axis in osteogenesis and chondrogenesis 
 
In addition to studies supporting the effect of ghrelin on regulating bone homeostasis 
(Amini et al., 2013; Choi et al., 2013), ghrelin appears to have a role in bone 
development (osteogenesis) and repair (Deng et al., 2008). In a ghrelin 
supplementation model in rats, increased bone formation was observed in calvarial 
bone defects in animals treated with ghrelin, suggesting that ghrelin enhances 
intramembranous ossification during bone healing (Deng et al., 2008). Ghrelin may also 
play a role in chondrogenesis (Caminos et al., 2005; Gomez et al., 2009). Ghrelin, 
stimulates cAMP production in cartilage cells (chondrocytes) in vitro, and induces a 
significant increase in the gene expression of chondroitin sulphate type IV (a 
proteoglycan synthesis gene) in human and murine chondrocytes (Caminos et al., 
2005). An increase in cAMP is linked with increased chondrocyte apoptosis and it is 
hypothesised that ghrelin may play a regulatory role in chondrocyte metabolism, 
 
 
22 
 
promoting hypertrophic processes by increasing proteoglycan synthesis and 
programmed cell death (Caminos et al., 2005).   
 
GHSR1a mRNA and protein are expressed in rat fetal ribs (Nakahara et al., 2006), but 
expression has not been localized to particular cell types. GHSR1a may be expressed 
in osteoblasts and/ or osteoclasts of costal cartilage, which are present at the sternal 
ends of the ribs. It is unclear from the study by Nakahara et al. (2006) whether GHSR1a 
plays a role in chondrogenesis or osteogenesis and this remains to be clarified. It has 
been reported that ghrelin (peptide and mRNA) are expressed by a mouse immortalised 
chondrocyte cell line (ATDC-5), juvenile human immortalised chondrocyte cell lines 
(T/C-28a2, C-20/A4 and C-28/I2) and rat epiphyseal growth plate chondrocytes (in fetal 
and postnatal rats aged 1 day, 15 days and 25 days) (Caminos et al., 2005). GOAT is 
also expressed in cultured primary human chondrocytes (derived from human articular 
cartilage), human immortalised chondrocyte cell lines (T/C-28a2 and C-28/I2) and 
immortalised mouse chondrocytes (ATDC-5) (Gomez et al., 2009). Although these 
reports indicate that acylated ghrelin is synthesised and secreted by chondrocytes, the 
study (Caminos et al., 2005) failed to identify GHSR1a mRNA in chondrocytes of the rat 
epiphyseal growth plates (in fetal and postnatal rats aged 1 day, 15 days and 25 days) 
and human immortalised chondrocyte cell lines (T/C-28a2, C-20/A4 and C-28/I2) 
(Caminos, et al., 2005). Binding studies (using 125-I ghrelin) in human immortalised 
chondrocytes (T/C-28a2) suggested the presence of alternative ghrelin binding 
receptors (Caminos et al., 2005). Ghrelin treatment also increased cAMP production 
and inhibited chondrocyte metabolic activity in human (T/C-28a2) and mouse (ATDC-5) 
immortalised chondrocytes (Caminos et al., 2005). These reports indicate that 
chondrocytes produce desacyl and acyl ghrelin which signal through alternative 
receptors and modulate chondrocyte metabolism in the cartilage template for 
endochondral ossification. The failure to detect GHSR1a in chondrocytes is challenged 
by data on Geo Profiles in NCBI showing that human osteoarthritic chondrocytes in 
monolayer and matrix cultures express GHSR 
(http://www.ncbi.nlm.nih.gov/geoprofiles/67009914). Therefore, it is necessary to further 
explore the expression of the ghrelin axis in chondrocytes.  
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Osteogenesis and chondrogenesis are essential processes involved in skeletal 
development (Olsen et al., 2000). Therefore, the ideal model for studying the expression 
of the components of the ghrelin axis on cells involved in osteogenesis and 
chondrogenesis are fetuses at different stages of development.  
 
 
1.7 Significance, Hypothesis and Aims 
 
Metabolic bone diseases are a significant health burden in society and understanding 
bone physiology could lead to improvements in therapeutic and management strategies. 
Endogenous chemicals regulate bone metabolism and the ghrelin axis could have an 
association with the regulation of the bone microenvironment. Characterisation of the 
bone microarchitecture by 3D micro-computed tomography (micro-CT) in GHSR1a 
knockout mice indicates that ghrelin, signalling through GHSR1a, may play an important 
role in maintaining bone microarchitecture with progressing age (van der Velde et al., 
2012). However, the high level of constitutive activity of GHSR1a (Holst et al., 2003) 
and presence of alternative receptors through which acyl ghrelin and des acyl ghrelin 
could signal in the absence of GHSR1a (Caminos et al., 2005; Muccioli et al., 2004; 
Thielemans et al., 2007; Volante et al., 2003), provide doubt whether or not \ acyl 
ghrelin signalling through GHSR1a is solely responsible for the microarchitectural 
changes observed. Therefore, we proposed that the characterisation of the bone 
phenotype of GOAT knockout mice at different ages would contribute critical information 
regarding whether acyl ghrelin signalling through GHSR1a is responsible for regulating 
microarchitecture of bone with increased age. We hypothesise that acyl ghrelin 
signalling through GHSR1a plays a key role in maintaining the micro-architecture of 
both trabecular and cortical bone (Caminos et al., 2005; Muccioli et al., 2004; 
Thielemans et al., 2007; Volante et al., 2003). 
 
There is evidence that the ghrelin axis plays a role in chondrogenesis and further 
investigation may lead to opportunities to target the axis for treating cartilage disorders 
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such as articular cartilage injuries and developmental disorders of cartilage metabolism, 
such as chondrodysplasias. Ghrelin is expressed in human and mouse cell lines in vitro 
and on rat chondrocytes of the epiphyseal growth plate (Caminos et al., 2005). 
Chondrogenesis is a key process involved in the establishment of the framework for 
endochondral bones in the skeleton during fetal development. The expression of the 
ghrelin axis (with the exception of GOAT), has not been investigated in primary human 
chondrocytes (Clarke, 2008; Mackie et al., 2008), which may be a more clinically 
relevant model for investigating the therapeutic potential of the ghrelin axis for cartilage 
disorders. We hypothesise that the ghrelin axis is expressed in primary human 
chondrocytes and plays a regulatory role in chondrogenesis. GHR is expressed by 
chondrocytes of the primordial sternum and costal cartilages of human fetuses in the 
second trimester (Clarke, 2008; Mackie et al., 2008; Werther, Haynes, Edmonson, et 
al., 1993; Werther, Haynes, & Waters, 1993; Werther et al., 1990). Therefore, we 
hypothesise that both GHR and the ghrelin axis are expressed in first trimester 
chondrocytes in the endochondral bones of the human skeleton. 
  
Due to ethical limitations and the scarcity of human fetal tissues, investigations of bone 
formation and the regulators of endochondral bone formation have been widely carried 
out in vitro and on animal models. This presents the challenge of translating the 
outcomes of in vitro and animal experiments to the physiological regulation of 
endochondral bone formation in humans. We hypothesise that the GH axis and the 
ghrelin axis together play a role during fetal skeletal development in humans and 
rodents (mouse).    
The overall aims of this project to test the above hypotheses were: 
Aim 1: Characterise the microarchitecture of trabecular and cortical bone of GOAT-/- 
mice with advancing age in comparison to wild type mice. 
Aim 2: Compare the expression of ghrelin, GHSR1a and GHR in fetal skeletal 
chondrocytes of human endochondral bones from the first trimester and murine 
cartilage templates at E14.5, E16.5 and E18.5. 
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Chapter 2 
 
General Materials and 
Methods 
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2.1 Ethics and source of materials 
2.1.1 Source of animals and animal ethics 
 
Aim1 
C57BL/6 wildtype (WT) and ghrelin O-acyl transferase knockout (GOAT-/-) mice were 
used to characterise the bone morphology of GOAT-/- mice. Animal use was approved 
by the Animal Ethics Committee of the University of Queensland and approval was 
ratified by the Queensland University of Technology University Animal Ethics 
Committee (UAEC approval number TRI/509/12/QUT). C57BL/6J WT female mice aged 
6 months (n=7), 9 months (n=5) and 18 months (n=4) were obtained from the University 
of Queensland Biological Resources Centre or the Animal Resources Centre, Western 
Australia. GOAT-/- mice (on a C57BL/6J background) were generated at Taconic animal 
laboratories (US) and were provided under a material transfer agreement between Dr 
Jeffery and Eli Lilly (Indiana, USA and Professor Matthias Tschop). The mice were re-
derived and bred at the Mater Medical Research Institute and Translational Research 
Institute (TRI). The genotypes of the mice were confirmed by PCR and ghrelin ELISA by 
Dr Jeffery. Female GOAT-/- mice aged 6 months (n=5), 9 months (n=5) and 18 months 
(n=7) were available for this project. 
 
On a normal diet, GOAT-/- mice gain weight normally, however, they gain less weight 
than WT mice on a high fat diet. The phenotype of this strain has been published 
previously by our collaborators (Kirchner et al., 2009). Although previously unreported, 
GOAT-/- mice are susceptible to stress and displayed greatly reduced fecundity after 
transfer to TRI, hence sample numbers and timepoints had to be reduced. 
 
Aim 2 
C57BL/6J mouse embryos aged 14.5 days (n=3), 16.5 days (n=3) and 18.5 days (n=3) 
post conception were provided by Dr. Rebecca Pelekanos (University of Queensland 
Centre for Clinical Research, Royal Brisbane Hospital). Ethics was approved by the 
Animal Ethics Committee of the University of Queensland (Ethics approval: University of 
Queensland Centre for Clinical Research project number 2009000508-NHMRC).   
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2.1.2: Human ethics 
 
Products of human conception (6-12 week old embryos/fetuses, n=9) following 
termination of pregnancy by vacuum aspiration were provided by Dr. Rebecca 
Pelekanos (University of Queensland Centre for Clinical Research, Royal Brisbane 
Hospital). Ethics was approved by The Human Research Ethics Committee of the Royal 
Brisbane and Women’s Hospital (Ethics approval: University of Queensland Centre for 
Clinical Research project number 2009000508-NHMRC). 
 
 
2.2.1 Characterisation of bone microarchitecture of GOAT-/- mice  
 
To determine a role of acyl ghrelin signalling in the regulation of the bone micro-
environment with age, the microarchitecture of femoral and tibial trabecular and cortical 
bone tissues were compared between GOAT-/- and WT mice at different ages using 
micro-computed tomography (micro-CT). For this project, female GOAT-/- and WT mice 
of three age categories (6, 9 and 18 months; n=4-7 mice per group) were used to 
analyse the bone tissue phenotypes at different stages of the adult mouse lifecycle. The 
desired sample size of for each group at each age was 7 which was determined by 
using the power calculation [(21.0*SD2)/(mean1-mean2)2], with a substantive difference 
of 20% based on data for callus size from Ekholm, et al., 2002 and for chondrocyte 
proliferation from (Z. Liu, Lavine, Hung, & Ornitz, 2007).  The numbers, however, were 
not even due to the challenge of maintaining the GOAT-/- mice as a result of increased 
susceptibility to stress and greatly reduced fecundity.  The normality tests used for 
analysis, the Kolmogorov-Smirnov test requires 5 or more values. The Shapiro-Wilk test 
requires 7 or more values and the D'Agostino test requires 8 or more values. The 
Kolmogorov-Smirnov test was used for parameters of mice with sample numbers of 
more than 5, and this resulted in a p>0.05, showing that the data are not inconsistent 
with a Gaussian distribution. Normal distribution was assumed for sample numbers less 
than 4 as previous studies such as van der Velde et al, 2012 showed that the 
distribution of parameters in the ghsr1a mice follow normal distribution. With smaller 
 
 
28 
 
data sets the normality tests do not have much power to detect modest deviations from 
the Guassian ideal (Harvey, 2013).   
 
 
2.2.2: Housing, Injections, Euthanasia and Tissue Sampling 
 
Animal experimentation was carried out at the vivarium at Pharmacy Australia Centre 
for Excellence (PACE) and the Mater Medical Research Institute (MMRI) following a 
week’s acclimatisation after the introduction to the animal facilities. All animals were 
housed in a maximum of 4 per cage, had unlimited access to chow diet and water, and 
a daily diurnal light cycle of 12 hours. Female GOAT-/- mice and WT mice aged 6 
months (n=5), 9 months (n=5) and 18 months (n=7) were sacrificed by carbon dioxide 
asphyxiation. This involved placing each mouse in an empty enclosed chamber and 
introducing carbon dioxide gas. Euthanasia was confirmed by observing the cessation 
of a number of vital signs, including the lack of respiration.  The mice were radiographed 
on a Kodak, in vivo X-ray machine to visualise any skeletal abnormalities.  
 
The lower limbs of each mouse were extracted by removing the fur and skin from the 
hip joints to the feet, removing muscles and cutting around the hip joint. The tibiae and 
femora were separated and the length of each bone was measured with a ruler. To 
allow fixative to enter the medullary cavity, the femoral head and distal tibial epiphysis 
were removed with scissors. The tissues were fixed in freshly prepared 4% 
paraformaldehyde (PFA) in 0.1M PBS for 18-24 hours at 4◦ C. Following fixation, the 
right femora and tibiae were transferred to 70% ethanol for micro-CT scanning and 
processing for dynamic histomorphometry and the left femora and tibiae were 
transferred to 14% EDTA in distilled water (pH=7.2) for decalcification for 3 week with 
changes to fresh EDTA every 3 days. 
 
 
2.2.3: Micro-computed tomography scanning and evaluation 
 
The right femora and tibiae were scanned and analysed using the Scanco µCT 40 
desktop microCT scanner (Scanco Medical, Brϋttisellen, Switzerland). The samples 
were wrapped in bench cloth moistened with 70% ethanol, to prevent the sample from 
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moving and drying out during the scan. Samples were contained within a sample tube 
with an internal diameter of 10mm containing 70% ethanol. The samples were scanned 
with an X-ray power of 55kV and tube current of 144µA to achieve a scanning resolution 
of 12µm. The femora were scanned from the distal end of the femoral neck to the distal 
articular surface of the femur (as shown in Figure 2.2.3-1) and the tibiae were scanned 
from the proximal articular surface of the tibia to the distal part of the tibia where the 
fibula attaches (as shown in Figure 2.2.3-1). Following scanning, the trabecular and 
cortical bone tissues were evaluated for the following parameters from reconstructed 
cross-sectional images, in order to distinguish between the microarchitectural and 
material properties between the trabecular and cortical compartments of GOAT-/-  and 
WT mice.   
Femur      Tibia 
                                                   
Figure 2.2.3-1. Scanned regions of femora and tibiae for microCT analysis. Each 
radiograph is an anteroposterior view. 
 
 
Trabecular bone measurements: The regions of interest for trabecular bone 
measurements were the secondary spongiosa of the distal femoral metaphysis and 
proximal tibial metaphysis. These regions were defined by firstly excluding the 40 scan 
slices (each slice = 12µm) immediately adjacent to the epiphyseal growth plate within 
the diaphysis of each bone. This region corresponds to the primary spongiosa where 
new bone is generated from the active epiphyseal growth plate (which is the site of 
longitudinal bone growth). Second, the subsequent 150 (1.8mm) serial slices of the 
Scanned region  
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metaphysis were selected for evaluation. The area of interest of each slice was selected 
by drawing contour lines around the trabecular bone tissue along the inner margin of the 
cortical bone to exclude the cortex (as shown in Figure 2.2.3-2). Material bone mineral 
density (BMD), bone volume fraction (BV/TV), trabecular number (Tb.N), trabecular 
thickness (Tb.Th), trabecular separation (Tb.Sp) and connectivity density (Conn. Den) 
were determined using the direct model of the in-built evaluation script for trabecular 
measurements of the Scanco µCT 40 desktop microCT scanner. 
 
Cortical bone measurements: The region of interest for cortical measurements was 
the mid-diaphyses of the femur and tibia. The start of this region was selected by 
dividing the total number of slices of the specimen by 2 and substracting 10 slices 
towards the distal femoral growth plate for the femur or the proximal tibial growth plate 
for the tibia. From this point 20 slices towards the proximal femoral growth plate for the 
femora and 20 slices for the distal tibial growth plate for tibiae were evaluated for 
material bone mineral density (BMD) and polar moment of inertia (pMOI) using the 
evaluation script for cortical measurements.  
 
One mid-slice of each region of interest was exported to the Osteomeasure software 
(Osteometrics, Atlanta, Georgia, USA) in TIFF format converted to RGB using GIMP2 
software. Contour lines were drawn around the cortical perimeter and marrow perimeter 
of each slice (as shown in Figure 2.2.3-2) to obtain values for cortical bone area, mean 
cortical width, endosteal circumference and periosteal circumference. 
 
 
2.2.4 Statistical Data analysis 
 
All data was analysed using GraphPad Prism 6, statistics analysis software program 
(San Diego, CA). The Kolmogorov-Smirnov test was used for parameters of mice with 
sample numbers of more than 5, and this resulted in a p>0.05, showing that the data 
are not inconsistent with a Gaussian distribution. Guassian distribution was assumed for 
sample sizes less than 5 as previous studies such as van der Velde et al., 2012 have 
shown that these parameters show a normal distribution. Comparison of the results 
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between GOAT-/- and WT was performed using independent Student’s t-test and 
comparison between the ages for each group was performed using the one-way 
ANOVA with Tukey’s post hoc analysis. Probability values of p<0.05 were considered 
statistically significant and 0.1>p>0.05 was considered marginally significant (Gregory, 
et al., 2006). Results were expressed as the mean value± standard error of mean 
(S.E.M). 
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Figure 2.2.3-2. Three dimensional images of the femur (A) and tibia (B) showing the 
selected region of interest for trabecular measurements (C) and 2D cross sectional slice 
from the ROI in the femur (D) and tibia (E) showing the green contour lines drawn to 
define the area of interest in the cross sections. 
 
 
 
A    
D 
B 
 
C 
E 
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2.3 Immunohistochemistry and Tartrate Resistant Acid Phosphatase staining  
2.3.1: Optimisation of primary antibodies for immunostaining mouse bone tissue 
sections  
 
Decalcified left femora and tibiae were processed, paraffin embedded and 3µm sections 
mounted on Superfrost slides. Sections of 8 day old, 8 week old and 6 month old wild 
type (WT) mice were immunostained to optimise primary antibody dilutions for the 
expression of ghrelin, GHSR1a, GOAT, osteocalcin, and runx2. The sections were 
deparaffinised in Solv21C (Muraban Laboratories, Brisbane), followed by rehydration in 
a series of graded ethanol (3 times in 100%, 90% and 70% ethanol) then phosphate 
buffered saline (PBS). Antigen retrieval was performed by microwave heating the 
sections in 10mM sodium citrate buffer pH 6.0 containing 0.05% (v/v) Tween-20 for 20 
minutes. After cooling, endogenous peroxidase activity was blocked with 3% H2O2 for 
10 minutes at room temperature. The sections were washed in PBS and non-specific 
antibody binding was blocked by incubating the sections in 1% BSA in PBS+0.1% 
Tween for 1 hour at room temperature. The sections were then incubated with the 
primary antibodies diluted in blocking buffer at 4°C overnight, with antibody dilutions of 
1:100, 1:250, 1:500 and 1:1000 for rabbit polyclonal anti-mouse ghrelin (Phoenix 
Pharmaceuticals Inc., H-031-31), goat polyclonal anti-human GHSR1a diluted 1:100 
(Santa Cruz Biotechnology, F-16), goat anti-human GOAT antibody (Abcam, ab-
170690), goat anti-human MBOAT4 antibody (Santa Cruz Biotechnology, sc-98001), 
anti-human runx2 antibody (Abcam, ab23981) and anti-human osteocalcin (Santa Cruz 
Biotechnology, sczsc-30044). Antibody dilutions of 1:100, 1:250, 1:500, 1:1000 were 
used. Negative control tissue used were GOAT-/- mouse stomach tissues for GOAT 
antibodies and for all antibodies the primary antibody was replaced with normal goat 
IgG diluted 1:100 (Santa Cruz Biotechnology, sc-2755), or rabbit IgG 1:100 (Santa Cruz 
Biotechnology, sc-2763) for GHSR1a, ghrelin, osteocalcin and runx2 antibodies. 
Sections were washed in PBS+0.1% Tween (PBST) and incubated with horse radish 
peroxidase (HRP) rabbit or goat polymer conjugates (Biocare Medical) for 30 minutes. 
Sections were washed with PBST and stained with the chromogen diaminobenzidine 
(DAB, Invitrogen). All immunostained sections were lightly counterstained with Mayers 
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haematoxylin, air dried overnight and coverslipped using DPX mounting medium (Sigma 
Aldrich). Sections were visualised under a standard light microscope for the staining 
patterns.  
 
 
2.4.2: Tartrate resistant acid phosphatase (TRAP) staining and osteoclast 
quantification 
 
One section of the left tibia and femur of each WT and GOAT-/- mouse aged 6 month 
old, 9 month old and 18 month old were TRAP stained to determine osteoclast number 
on the trabecular bone surface in the secondary spongiosa of the distal femoral 
metaphysis and proximal tibial metaphysis. This was done to determine whether 
osteoclast activity is altered in the absence of acyl ghrelin signalling. GHSR-/- mice have 
been reported to have increased osteoclast numbers on the trabecular bone surface at 
6 months of age (van der Velde et al., 2012).  Naphthol-ASTR phosphate (Sigma, N-
6125) was made to a concentration of 10mg/ml in N, N-dimethyl formamide and 4ml 
was mixed in 60 ml of 0.05M Tris-HCl (staining buffer, pH 9.0). Pararosaniline-HCl 
(Sigma, P-3750) at concentration of 40mg/ml and sodium nitrite at a concentration of 
40mg/ml in distilled water was mixed in equal volumes (total volume= 10% of staining 
mixture) and added to the staining mixture. The mixture was stirred and 10% sodium 
tartrate (Sigma, S-8640) was added to the mixture and the pH was adjusted to 5.0 with 
10M sodium hydroxide. The mixture was filtered into a coplin jar through a No. 1 
Whatman filter paper. The sections were de-waxed in xylene (3 washes at  5 minutes 
each), rehydrated in a graded series of alcohols (3 X 100% ethanol, 2 X 90% ethanol, 1 
X 70% ethanol, 1 X 50% ethanol for 5 minutes each) to running distilled water for 5 
minutes.  The sections were incubated in the TRAP mixture at 37°C in an oven for 20-
30minutes for colour development. Colour development (presence of red stained 
osteoclasts) was checked at 20, 25 and 30 minutes under a light microscope. Once 
colour development was confirmed, the sections were washed in running tap water for 
10 minutes, lightly counterstained with Mayer’s haematoxylin for 5 minutes and washed 
in running tap water for 10 minutes. The sections were dried overnight and coverslipped 
with an aqueous mounting medium (CC/MountTM, Sigma, C9368).  
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Osteoclast numbers on the trabecular bone surface of the secondary spongiosa of the 
distal femoral metaphysis and proximal tibial metaphysis of the stained sections were 
determined by obtaining images of each section at a magnification of 200x using a light 
microscope (Zeiss), connected to a computer installed with the Osteomeasure program 
(Osteometrics, Atlanta, Georgia, USA). The secondary spongiosa of each section was 
chosen by excluding 350µm from the lowest end of the growth plate and selecting the 
subsequent 1.5mm of the adjacent region of the metaphysis. The trabecular bone 
perimeter of the secondary spongiosa of the image on the Osteomeasure program was 
defined by drawing around the surface using a digitised pen and selecting the 
osteoclasts on the surface to define osteoclast numbers on the trabecular bone surface.  
 
 
2.5 Expression of the growth hormone secretagogue receptor 1a (GHSR1a) and 
the growth hormone receptor (GHR) in human and mouse fetal chondrocytes 
 
Vertebral columns, upper limbs and lower limbs were harvested from human fetuses 
(n=8) with a gestational age of 6-12 weeks. The human tissues, together with mouse 
embryos at post-conception age 14.5 (n=3), 16.5 (n=3) and 18.5 (n=3) were fixed in 4% 
PFA for 24 hours at 4˚C. The tissues were processed and embedded in paraffin by the 
histology services at Queensland Institute of Medical Research (QIMR) or University of 
Queensland Diamantina Institute (UQDI).  
 
 
2.5.1 Immunohistochemistry for protein expression on human fetal chondrocytes 
 
The paraffin-embedded tissue blocks were sectioned at 5µm thickness on a rotary 
microtome (Leica RM2235) onto Superfrost slides (HDScientific, HD41800) and 
deparaffinised in Solv21C (Muraban Laboratories, Brisbane), followed by rehydration in 
a series of graded ethanol (3 times in each solution of 100%, 90% and 70% ethanol) to 
phosphate buffered saline (PBS). Antigen retrieval was performed by microwave 
heating the sections in 10mM sodium citrate buffer pH 6.0 containing 0.05% (v/v) 
Tween-20 for 20 minutes. After cooling, endogenous peroxidase activity was blocked 
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with 3% H2O2 for 10 minutes at room temperature. The sections were washed in PBS 
and non-specific antibody binding was blocked by incubating the sections in 1% BSA in 
PBS+0.1% Tween for 1 hour at room temperature. The sections were then incubated 
with the primary antibodies diluted in blocking buffer with optimised antibody 
concentrations of 1:100, 1:250, 1:500 and 1:1000 diluted in the blocking buffer (1% BSA 
in PBS+0.1% Tween). The final antibody dilutions as shown in Table 2.3-1 were rabbit 
polyclonal anti-ghrelin diluted 1:500 (Phoenix Pharmaceuticals Inc., H-031-31; cross 
reactive with human, mouse and rat ghrelin), rabbit polyclonal growth hormone receptor 
antibody diluted 1:100 (Santa Cruz Biotechnology, H-300; cross-reactive with human, 
mouse and rat GHR) and goat polyclonal anti-GHSR1a diluted 1:100 (Santa Cruz 
Biotechnology, F-16; cross reactive with human, mouse and rat GHSR1a) at 4˚C 
overnight. For negative controls the primary antibody was replaced with normal goat 
IgG diluted 1:100 (Santa Cruz Biotechnology, sc-2755), or rabbit IgG 1:100 (Santa Cruz 
Biotechnology, sc-2763). Sections were washed in PBS+0.1% Tween (PBST) and 
incubated with horse radish peroxidase (HRP) rabbit or goat polymer conjugates 
(Biocare Medical) for 30 minutes. Sections were washed with PBST and stained with 
the chromogen diaminobenzidine (DAB, Invitrogen). All immunostained sections were 
lightly counterstained with haematoxylin, air dried overnight and coverslipped using 
DPX mounting medium (Sigma Aldrich). Mouse brain tissues were immunostained for 
use as positive controls for anti-GHSR1a and mouse liver tissues were immunostained 
for positive control as growth hormone receptor antibody. The GHSR1a antibody has 
been previously validated on GHSR knockout mice (Shin et al., 2010) and in 
mammalian cells by our group (Fung et al., 2013). Mouse stomach, which is known to 
express high levels of ghrelin and GOAT, was used as positive control for anti-ghrelin 
antibody and anti-GOAT antibodies.  
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Table 2.5-1: Primary antibodies and dilutions used in immunohistochemistry for human 
tissues and mouse embryos 
Antibody and 
species specificity 
Host species Optimised 
dilution 
Supplier & 
catalogue number 
Anti-mouse ghrelin Rabbit 1:500 Phoenix 
Pharmaceuticals Inc 
(H031-31) 
Growth hormone 
receptor (human) 
antibody 
Rabbit 1:100 Santa Cruz 
Biotechnology 
(H300) 
anti-human growth 
hormone 
secretagogue 
receptor 1a 
Goat 1:100 Santa Cruz 
Biotechnology (F16) 
IgG Rabbit 1:100 Santa Cruz 
Biotechnology 
(sc2763) 
IgG Goat 1:100 Santa Cruz 
Biotechnology 
(sc2755) 
 
2.3.2 Safranin O/Fast green staining 
 
To determine the morphology of chondrocytes in order to identify the cells that were 
immunostained, safranin O/fast green staining was performed on the fetal sections. The 
sections were deparaffinised in xylene and rehydrated in a graded series of ethanol 
(100% X3, 90%, 70%) to distilled water. The sections were stained with freshly made 
Weigert’s haematoxylin (1.5% aqueous ferric chloride 1ml HCL mixed in equal amounts 
with 1% haematoxylin) for 10 minutes, washed in distilled water and differentiated in 
0.5% acid alcohol. The sections were washed in distilled water, blued in 0.1% ammonia 
and stained with 0.2% fast green solution (Sigma Aldrich) for 5 minutes. The sections 
were then rinsed in 1% acetic acid, stained with 0.1% Safranin O for 1 minute and 
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dehydrated in a graded series of ethanol (70%, 90% and 3 X 100%) to xylene. The 
stained sections were mounted using DPX mounting medium (Sigma Aldrich) and 
visualised by light microscopy. 
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Chapter 3 
 
The microarchitecture of 
bone in GOAT knockout 
mice 
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3.1 Introduction 
 
The ghrelin axis has many roles in physiological processes including the regulation of 
growth hormone secretion (Kojima et al., 1999), appetite (Wren et al., 2000) and energy 
balance (Kirchner et al., 2012). Accumulating evidence from recent reports indicates 
that ghrelin may have a positive regulatory role in bone metabolism (Amini et al., 2013; 
Costa et al., 2011; Fukushima et al., 2005; Kim et al., 2005; van der Velde et al., 2012). 
Several studies on human populations (particularly in females) have shown a positive 
correlation between circulating ghrelin levels and bone mineral density (BMD), 
independent of confounding factors such as body mass index (BMI), physical activity, 
age, alcohol consumption and smoking (Amini et al., 2013; Misra et al., 2005; Napoli et 
al., 2011; Nouh et al., 2012; Oh et al., 2005; Weiss et al., 2006). 
 
Ghrelin and GHSR1a are expressed by osteoblasts (P. J. Delhanty et al., 2006; 
Fukushima et al., 2005; Kim et al., 2005; Liao L. & Wang, 2010; Maccarinelli et al., 
2005) and ghrelin has positive effects on the proliferation of rat, mouse and human 
osteoblasts (Costa et al., 2011; P. J. Delhanty et al., 2006; Fukushima et al., 2005; Kim 
et al., 2005; Liao L. & Wang, 2010; Maccarinelli et al., 2005) and differentiation of 
mouse and rat osteoblasts (Fukushima et al., 2005). In contrast to osteoblasts, only a 
few studies have reported that ghrelin has a role in osteoclast function. Ghrelin and 
GHSR1a are expressed by mouse osteoclasts (van der Velde et al., 2012) and ghrelin 
has been reported to increase rat osteoclast resorption (Costa et al., 2011). These 
studies suggest that ghrelin may directly regulate the function of both osteoblasts and 
osteoclasts.  
 
In vivo, ghrelin administration has been shown to have an anabolic effect on bone in 
Sprague Dawley rats aged 6 weeks as it increases BMD (Fukushima et al., 2005). The 
anabolic effects of ghrelin administration is contradicted by reports that BMD is not 
affected in 8 week old ghrelin deficient (Sun et al., 2003) and 24 week old GHSR 
deficient (Sun et al., 2004) mice compared to age matched, WT controls. This suggests 
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that ghrelin may contribute to the short-term improvement in bone strength by affecting 
the material properties of bone.  
 
In vivo, ageing has been shown to have a significant impact on the activity of ghrelin as 
indicated by the microarchitecture of GHSR-deficient (GHSR-/-) mice (van der Velde et 
al., 2012). Three dimensional (3D) micro-CT analyses of the trabecular and cortical 
bone microarchitecture of the left femora of GHSR-/- mice aged 3 and 6 months have 
shown that the 6 month old GHSR-/- mice have reduced trabecular bone volume 
fraction, trabecular number, cortical volume and polar moment of inertia compared to 
age matched WT controls (van der Velde et al., 2012). The microarchitecture of GHSR-/- 
mice aged 3 months was not significantly different to the WT controls (van der Velde et 
al., 2012). Furthermore, this study showed that the GHSR-/- mice showed a higher 
number of osteoclasts compared to WT controls in both 3 and 6 month old animals. 
Since the micro-architectural differences were observed at only 6 months, this may 
indicate that a systemic or central process overrides the local stimulation of osteoclast 
activity at younger ages (van der Velde et al., 2012). Ghrelin may also signal through 
alternative receptors (Caminos et al., 2005; Thielemans et al., 2007; Volante et al., 
2003) in bone in the absence of GHSR1a. The possibility that ghrelin signalling may 
have continued through compensatory pathways in these GHSR knockout mice cannot 
be excluded. As GHSR1a also possesses a high level of constitutive activity (Holst et 
al., 2003), the findings in the GHSR-/- mice do not confirm that acyl ghrelin signalling 
through GHSR1a is solely responsible for the observed effects and further studies are 
required. We hypothesise that employing GOAT-/- mice, which are unable to produce 
acyl ghrelin may provide additional information on the relative contributions of acyl 
ghrelin, desacyl ghrelin and the GHSR1a and their role in maintaining bone micro-
architecture with age. This study aimed to characterise the trabecular and cortical bone 
microarchitecture of female GOAT-/- mice at different adult ages through µCT.  
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3.2 Methods 
 
This study was carried out as detailed in Chapter 2 section 2.2.2 and 2.2.3. In brief, 
female C57/BL6 GOAT-/- and C57/BL6 WT mice aged 6, 9 and 18 months were 
euthanised and weighed. The right femora and tibiae were harvested, fixed and 
scanned in ethanol using a Scanco µCT 40 desktop microCT scanner (Scanco Medical, 
Brüttisellen, Switzerland). Trabecular micro-architectural measurements were carried 
out on the secondary spongiosa of the distal femoral metaphysis and proximal tibial 
metaphysis of reconstructed cross-sectional images using the in-built Scanco µCT 40 
script for trabecular measurements. Cortical bone measurements were carried out on 
the mid-diaphyses of the femora and tibiae of reconstructed cross-sectional images and 
the cortical material BMD and polar moment of inertia were evaluated using the in-built 
Scanco µCT 40 script for cortical measurements. Osteomeasure software was used to 
measure other cortical parameters such as cortical bone area, mean cortical width, 
periosteal perimeter and endosteal perimeter from mid-diaphyseal cross-sections.  
 
 
3.3 Results  
 
3.3.1 Phenotype of GOAT-/- and WT mice 
 
The weight of each mouse was measured at the time of sacrifice using an electronic 
scale to ensure that weight was matched between the GOAT-/- (KO) and WT mice as 
weight differences would influence the microarchitectural strength of bone. Compared to 
WT control mice, the GOAT-/- mice used in this study were significantly heavier at 9 
(38.76g ±2.28, p=0.002) and 18 months of age (36.15g ±0.85, p=0.03) , however, there 
were no significant differences in weights between the WT and GOAT-/- at 6 months of 
age (Figure 3.3-1A). WT mice showed an increase in weight with age with a statistically 
significant increase between 9 (28.94g ± 0.26) and 18 months of age (32.3g ±1.36, 
p=0.028). GOAT-/- mice showed an earlier increase in weight with increasing age than 
WT mice, where a significant increase was observed in GOAT-/- mice between 6 and 9 
months (p=0.007).  
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Figure 3.3-1A: Weights (g) of GOAT-/- (KO) and wildtype (WT) mice at 6, 9 and 18 
months of age measured at time of sacrifice. Statistically significance differences 
between means of GOAT-/- and WT mice was determined using independent Student’s t 
tests (GraphPad) and between the ages for each group using one-way ANOVA with 
Tukey’s post hoc analysis (GraphPad). Data represented as mean +/- standard error of 
the mean (SEM) and p<0.05 accepted as significant; a= p<0.05 compared to GOAT-/- at 
same age, b=p<0.05 compared to WT at 18 months of age, c=p<0.05 compared to 9 
month old GOAT-/-, d=p<0.05 compared to 18 month old GOAT-/-. 
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Radiographic (X-ray) images of the skeletons were taken at PACE at time of sacrifice to 
investigate presence of macroscopic phenotypic changes in the skeleton such as 
fractures, skeletal deformities or skeletal dysplasia or aplasia in the GOAT-/- and WT 
mice at 6 and 9 months of ages (Figure 3.3-1B). X-ray imaging could not be performed 
for the 18 month old GOAT-/- and WT mice as the necessary radiographic equipment 
was unavailable at the Mater Medical Research Institute (MMRI) where the 18 month 
old mice were housed. No differences in the upper limbs, lower limbs, vertebral 
columns, skulls or thorax, were observed in the radiographs between the GOAT-/- and 
WT mice aged 6 and 9 months.   
 
3.3.2 Trabecular bone micro-architecture of secondary spongiosa of the distal 
femoral metaphysis and proximal tibial metaphysis. 
 
In order to determine if acyl ghrelin affects bone microarchitecture, both femora and 
tibiae were chosen for evaluation of the trabecular micro-architecture. Representative 
3D CT volume-rendered models (Figures 3.3-2) demonstrated the trabecular bone 
present in the region of interest in the distal metaphyses of the femora (Figures 3.3-2A) 
and proximal metaphyses of the tibiae (Figure 3.3-2B) in the GOAT-/- and WT mice. A 
notable decline was observed in the trabecular bone volume fraction with advancing 
age between 6 and 9 months in the WT femora (Figure 3.3-2A) and tibiae (Figure 3.3-
2B). A smaller amount of trabecular bone occupied the volume of interest (VOI) in the 
GOAT-/- femora and tibiae compared to WT at 6 months of age (Figure 3.3-2). 
 
Bone mineral density (BMD) is a measure of the degree of mineralisation of the bone 
tissue and therefore represents the inorganic material properties of the bone which 
contributes to the strength of bone. The BMD of the trabecular bone was measured on 
the reconstructed cross sectional images from the microCT scan in the secondary 
spongiosa of the distal femoral metaphyses and the secondary spongiosa of the 
proximal tibial metaphyses, using the in-built evaluation script for trabecular 
measurements of the Scanco µCT 40 desktop microCT scanner. The material BMD of 
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Figure 3.3-1B: Representative radiographic (X-ray) images of 6 and 9 month old 
C57BL/6J GOAT-/- and WT mice. Mice are in a prone position on the film receptor. 
Abnormalities such as fractures, aplasias or dysplasias are not observable in the axial 
or appendicular skeletons of either GOAT-/- or WT mice. 
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Age (months) 6 9 18 
 
GOAT-/- 
 
 
  
 
 
WT 
 
  
Figure 3.3-2- Representative 3D micro-CT volume-rendered models of the secondary 
spongiosa of: A) the distal femoral metaphyses; and B) proximal tibial metaphyses of 
GOAT-/- and WT mice aged 6, 9 and 18 months. Note that these models represent the 
trabecular compartment only with the cortical shell extracted. Scale bar = 1.0mm. 
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Figure 3.3-3: Material bone mineral density (BMD, mgHA/ccm) of trabecular bone of the 
secondary spongiosa of the distal metaphyses of the right femora and proximal 
metaphyses of right tibiae of GOAT KO and WT mice aged 6, 9 and 18 months. 
Statistical significance between means of GOAT KO and WTs was determined using 
independent Student’s t tests (GraphPad) and between the ages for each group using 
one-way ANOVA with Tukey’s post hoc analysis (GraphPad). Significance accepted at 
p<0.05 and marginal significance accepted at p<0.1;, data represented as mean +/- 
standard error of the mean (SEM); a=p<0.05 compared to 18 months old WT femora, 
b=p<0.1 compared to 18 month old WT femora, c=p<0.05 compared to 18 month old 
GOAT KO tibiae, d=p<0.1 compared to 18 month old GOAT KO tibiae. 
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the secondary spongiosa of the distal metaphyses of the femora in WT mice showed a 
significant increase (p=0.01) in BMD with advancing age from 6 (864.05±12.58mgHA/c 
cm) to 18 months (947.88±26.86mg/HA/ccm), with greatest change observed between 
9 (877.61±11.53mgHA/ccm) and 18 months (p=0.05) (Figure 3.3-3); no significant age-
related change in BMD was observed in WT tibiae. The BMD of the secondary 
spongiosa of the proximal metaphyses of the tibiae of GOAT-/- mice showed a 
significant increase with advancing age from 6 (879.61±16.84 mgHA/ccm)) to 18 
(941.87± 48.84mgHA/ccm) months (p=0.014), and between 9 (941.80±8.630 mgHA/cc 
m) and 18 months (p=0.07) (Figure 3.3-3); no significant age-related change in BMD 
was observed in GOAT-/- femora. No significant differences were observed between the 
trabecular BMD of GOAT-/- and WT mice in the tibiae and femora at 6, 9 and 18 months 
of age. 
 
Trabecular bone volume fraction (BV/TV) is the volume of trabecular bone occupying 
the total volume of interest and is an indicator of overall bone mass. Due to the large 
surface area of trabecular bone tissue, changes in bone remodelling rates and altered 
bone cell function as a result of altered physiology, affects the bone volume fraction. 
BV/TV of the secondary spongiosa of the distal metaphyses of the right femora in 
GOAT-/- mice at 6 months of age (3.1% ±0.5) was significantly lower (p=0.005) 
compared to WT (6.2% ±0.6) controls (Figure 3.3-4). Similarly, BV/TV of the proximal 
metaphyses of the right tibiae of GOAT-/- mice aged 6 months (1.68% ±0.2) was 
significantly lower (p=0.007) compared to WT control mice (6.3% ±1.2) of the same age 
(Figure 3.3-4). BV/TV significantly decreased with advancing age in the femora of WT 
from 6 (6.2% ±0.6) to 9 months (3.0% ±0.8; p=0.02) and in the tibiae of WT mice from 6 
(6.3% ±1.2) to 9 months (2.3% ±0.8; p= 0.05) (Figure 3.3-4). No significant differences 
in BV/TV were observed in the tibiae and femora of GOAT-/- mice with advancing age.  
 
The number of bone trabeculae present within the tissue volume (trabecular number, 
Tb.N) contributes to the microstructural strength of bone. The in-built script determines 
Tb.N by computing the inverse of the mean distance between the mid-axes of adjacent 
trabeculae (Bouxsein et al., 2010). Tb.N of the femora of 9 month old GOAT-/- mice  
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Figure 3.3-4: Trabecular bone volume fraction (BV/TV, %) of the secondary spongiosa 
of the distal femoral metaphyses of right femora and proximal metaphyses of right tibiae 
of GOAT KO and WT mice aged 6, 9 and 18 months. Statistical significance between 
means of GOAT KO and WTs was determined using independent Student’s t tests 
(GraphPad) and between the ages for each group using one-way ANOVA with Tukey’s 
post hoc analysis (GraphPad). Significance accepted at p<0.05 and marginal 
significance accepted at p<0.1, data represented as mean +/- standard error of the 
mean (SEM); a=p<0.05 compared to GOAT KO femora at 6 months of age, b=p<0.05 
compared to GOAT KO tibiae at 6 months of age, c=p<0.05 compared to 9 months old 
WT femora, d=p<0.05 compared to 18 months WT femora, e=p<0.1 compared to 9 
months old WT tibiae f=p<0.05 compared to 18 months WT tibiae.  
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Figure 3.3-5: Trabecular number (Tb.N, #/mm) of the secondary spongiosa of the distal 
femoral metaphyses of right femora and proximal metaphyses of right tibiae of GOAT 
KO and WT mice aged 6, 9 and 18 months. Statistical significance between means of 
GOAT KO and WTs was determined using independent Student’s t tests (GraphPad) 
and between the ages for each group using one-way ANOVA with Tukey’s post hoc 
analysis (GraphPad). Significance accepted at p<0.05 and marginal significance 
accepted at p<0.1, data represented as mean +/- standard error of the mean (SEM); 
a=p<0.05 compared to GOAT KO femora at 9 months of age, b=p<0.1 compared to 18 
month old WT femora, c=p<0.05 compared to 9 month old WT femora, d=p<0.05 
compared to 18 month old GOAT KO femora,  e=p<0.1 compared to 9 month old WT 
tibiae, f=p<0.05 compared to 18 month old GOAT KO tibiae. 
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2.02 ±0.11mm-1) was significantly greater (p=0.005) than the WT aged 9 months (1.32 
±0.14mm-1) (Figure 3.3-5). Tb.N of the femora significantly decreased with advancing 
age in the GOAT-/- from 9 (2.02 ±0.11mm-1) to 18 months (1.43 ±0.12mm-1; p=0.01). 
Tb.N of the WT femora decreased significantly with advancing age from 6 (2.25 
±0.27mm-1) to 9 months (1.32±0.14mm-1;  p=0.04). Tb.N of the  tibiae in the GOAT-/- 
mice significantly decreased (p=0.007) with advancing age from 6 (1.91±0.18mm-1) to 
18 months (0.96 ±0.1211mm-1) with the greatest decrease being observed with marginal 
significance (p=0.05) with advancing age in the tibiae of WT from 6 (2.13 ±0.35 mm-1) to 
9 months (1.03 ±0.09mm-1) (Figure 3.3-5). 
 
The thickness of trabeculae within the bone volume (trabecular thickness, Tb.Th) is an 
index of the trabecular microstructure that provides strength to bone and reflects 
changes in the balance of osteoblastic and osteoclastic activity at bone remodelling 
sites. The micro-CT measurement is based on a sphere fitting method, where for Tb.Th 
measurement, the spheres are fitted to the trabecular struts. The diameter of the largest 
sphere that can be fitted through each voxel and is completely contained within the 
object is used to average the diameters and yield the Tb.Th value (Bouxsein et al., 
2010).  Tb.Th of the trabeculae in the distal femoral metaphyses of GOAT-/- mice (0.05 
±0.002 mm) was significantly lower (p=0.001) compared to WT (0.06 ±0.002 mm) mice 
at 9 months of age (Figure 3.3-6). Similarly, Tb.Th of the trabeculae in the proximal 
metaphyses of the tibiae was significantly lower (p=0.09) in the GOAT-/- (0.05 ±0.004 
mm) compared to WT mice (0.06 ±0.002 mm) aged 9 months (Figure 3.3-6). 
The trabecular separation (Tb.Sp) is an index that represents the distance between 
adjacent trabeculae and therefore the thickness of the marrow spaces within the 
trabecular bone microstructure. It therefore gives an indication of the porosity of the 
trabecular bone tissue. The algorithm used for measurements of the Tb.Sp is based on 
3D calculations, namely, a sphere fitting method, where the spheres are fitted to the 
marrow space (Bouxsein et al., 2010). The diameter of the largest sphere that can be 
fitted through each voxel and is completely contained within the background is used to 
average the diameters and yield Tb.Sp values (Bouxsein et al., 2010). Tb.Sp of the 
distal femoral metaphyses and the proximal tibial metaphyses. 
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Figure 3.3-6: Trabecular thickness (Tb.Th, mm) of the secondary spongiosa of the distal 
femoral metaphyses of right femora and proximal metaphyses of right tibiae of GOAT 
KO and WT mice aged 6, 9 and 18 months. Statistical significance between means of 
GOAT-/- and WTs was determined using independent Student’s t tests (GraphPad) and 
between the ages for each group using one-way ANOVA with Tukey’s post hoc analysis 
(GraphPad). Significance accepted at p<0.05 and marginal significance accepted at 
p<0.1, data represented as mean +/- standard error of the mean (SEM); a=p<0.05 
compared to GOAT KO femora at 9 months, b=p<0.1 compared to GOAT-/- tibiae at 9 
months.  
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Figure 3.3-7: Trabecular separation (Tb.Sp, mm) of the secondary spongiosa of the 
distal femoral metaphyses of right femora and proximal metaphyses of right tibiae of 
GOAT KO and WT mice aged 6, 9 and 18 months. Statistical significance between 
means of GOAT KO and WTs was determined using independent Student’s t tests 
(GraphPad) and between the ages for each group using one-way ANOVA with Tukey’s 
post hoc analysis (GraphPad). Significance accepted at p<0.05 and marginal 
significance accepted at p<0.1, data represented as mean +/- standard error of the 
mean(SEM); a=p<0.05 compared to GOAT KO femora at 9 months of age, b=p<0.1 
compared to GOAT KO tibiae at 9 months of age, c=p<0.05 compared to 9 month WT 
femora, d=p<0.05 compared to 18 month old GOAT KO femora, e=p<0.05 compared to 
9 month old WT tibiae, f=p<0.05 compared to 18 month old WT tibiae, g=p<0.05 
compared to 18 month old GOAT KO  tibiae. 
 
 
 
54 
 
Tb.Sp of the distal femoral and proximal tibial metaphyses in GOAT-/- mice at 9 months 
(0.49 ±0.02 mm and 0.71 ±0.09 mm, respectively) of age was significantly smaller 
(p=0.05 and p=0.01, respectively) than the WT controls at 9 months of age (0.85 ±0.12 
mm and 1.02 ±0.09 mm, respectively) (Figure 3.3-7). The GOAT-/- mice showed an 
increase in the trabecular separation at the distal metaphyses of femora with advancing 
age, from 9 (0.498 ±0.028) to 18 months (0.73 ±0.05mm) (p =0.0122) (Figure 3.3-7). 
GOAT-/- mice showed a significant steady increase in the trabecular separation at the 
proximal metaphyses of tibiae with advancing age, from 6 (0.46 ±0.04mm) to 18 months 
(1.09 ±0.11mm; p= 0.0009), with the greatest decrease observed between 9 (0.719 
±0.093) and 18 months (1.093 ±0.11mm; p=0.0300) (Figure 3.3-7). WT mice showed an 
increase in the trabecular separation at the distal femoral and proximal tibial 
metaphyses with advancing age, from 6 (0.48 ±0.05mm and 0.53±0.06mm, 
respectively) to 9 months (0.85 ±0.12mm and 1.02 ±0.09mm, respectively) (p=0.025 
and p=0.0019) (Figure 3.3-7).  
 
Connectivity density (C.Den) indicates the connectedness of the trabeculae in the 
trabecular bone network. Trabecular connections are critical for the maintenance of the 
trabecular microarchitecture and is a major determinant of bone strength. C.Den in both 
the trabecular network of the distal femoral metaphyses and the proximal tibial 
metaphyses of GOAT-/- mice (6.20 ±0.83 mm-3 and 0.85 ±0.34 mm-3, respectively) were 
significantly lower (p=0.03 and p=0.06, respectively) at 6 months of age compared to 
WT (23.06 ±5.89 mm-3 and 26.61 ±10.23 mm-3, respectively) (Figure 3.3-8). No further 
significant differences were observed in C.Den in the animals studied. 
 
 
3.3.3 Cortical bone micro-architecture of the mid-diaphyses of the femora and 
tibiae in GOAT-/- mice. 
 
The representative 2D microCT bone slices of the mid-diaphyses of femora and tibiae 
shown in Figures 3.3-9A and 3.3-9B, respectively, visually demonstrate that the cortical 
width (Ct.Wi) of the mid-diaphyses of femora of GOAT-/- mice is greater at 6 and 9  
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Figure 3.3-8: Connectivity density (per mm3) of the secondary spongiosa of the distal 
femoral metaphyses of right femora and proximal metaphyses of right tibiae of GOAT 
KO and WT mice aged 6, 9 and 18 months. Statistical significance between means of 
GOAT KO and WTs was determined using independent Student’s t tests (GraphPad) 
and between the ages for each group using one-way ANOVA with Tukey’s post hoc 
analysis (GraphPad). Significance accepted at p<0.05 and marginal significance 
accepted at p<0.1, data represented as mean +/- standard error of the mean (SEM); 
a=p<0.05 compared to GOAT KO femora at 6 months of age, b=p<0.05 compared to 
GOAT KO tibiae at 6 months of age. 
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months compared to the WT mice. Ct.Wi is also reduced in 18 month old GOAT-/- 
femora and tibiae compared to the 9 month old femora and tibiae. 
Material bone mineral density in cortical bone (cortical bone mineral density, Ct.BMD) is 
one of the material properties of the cortical bone and is an indicator of the degree of 
mineralisation of the cortical bone tissue providing strength to cortical bone. GOAT-/- 
mice showed a significantly higher Ct.BMD in the mid-diaphyses of the femur (p=0.05) 
at 6 months (1208.99±17.61 mgHA/ccm)  compared to WT (1115.16±16.34 
mgHA/ccm). At 6 months of age the GOAT-/- tibiae also had a significantly higher 
(p=0.04) Ct. BMD (1176.2±10.98 mgHA/ccm) compared to WT (1116.57±22.24). At 9 
months of age GOAT-/- femora (1241.22±14.33 mgHA/ccm) had significantly higher 
(p=0.04) Ct.BMD than WT femora (1197.81±8.77 mgHA/ccm). The GOAT-/- tibiae 
(1175.5±5.32 mgHA/ccm) at 9 months also had significantly higher (p=0.0003) Ct.BMD 
than WT tibiae (112.45±2.55 mgHA/ccm)  (and , (Figure 3.3-10). The Ct.BMD increased 
with advancing age in the WT femora between 6 (1115.16±16.34 mgHA/ccm) and 18 
months (1238.30±16.80 mgHA/ccm) (p=0.005) (Figure 3.3-10). 
 
The cortical bone width (Ct.Wi) is an indicator of bone modelling of the bone shaft 
through endosteal resorption and periosteal bone apposition. Ct.Wi was measured by 
exporting one cross sectional image from the microCT scan of the mid-diaphyses of 
tibiae and femora of GOAT-/- and WT mice from the Scanco µCT 40 desktop microCT 
scanner to the Osteomeasure software. Contour lines were drawn around the cortical 
periosteal perimeter and endosteal perimeter in the Osteomeasure software to generate 
the mean distance between the two contour lines, equating to Ct.Wi. In the mid-
diaphyses of GOAT-/- femora at 6 months (240.79±15.84 µm) and 9 months 
(222.57±6.54 µm), the Ct.Wi was significantly larger (p=0.0053 and p=0.0103, 
respectively) than WT femora of the same age (6 month: 174.99±7.17 mm; and 9 
month: 179.22±7.28 mm). Similar to the femora, the Ct.Wi of GOAT-/- tibiae at 6 months 
(202.17±5.67 mm) and 9 months (202.97±3.01 µm) were significantly higher (p=0.01 
and p=0.002, respectively) compared to WT (6 months: 168.24±8.63 µm; and 9 months: 
166.04±8.47 µm).  
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Figure 3.3-9: Representative 2D slices of mid-diaphyses of A) femora and B) tibiae 
evaluated for cortical bone architecture in GOAT-/- and WT mice aged 6, 9 and 18 
months. Scale bar = 1.0 mm, C=cortical bone, M=medullary cavity, green arrow shows 
the periosteum and blue arrow shows the endosteal surface of the cortex.   
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Figure 3.3-10: Material bone mineral density of cortical bone (Ct.BMD, mgHA/cm3) of 
the mid-diaphyses of the right femora and right tibiae in GOAT KO and WT mice aged 
6, 9 and 18 months. Statistical significance between means of GOAT KO and WTs was 
determined using independent Student’s t tests (GraphPad) and between the ages for 
each group using one-way ANOVA with Tukey’s post hoc analysis (GraphPad). Data 
represented as mean +/- standard error of the mean (SEM), significance accepted at 
p<0.05 and marginal significance accepted at p<0.1; a=p<0.05 compared to GOAT KO 
femora at same age, b=p<0.05 compared to GOAT KO tibiae at same age, c=p<0.05 
compared to 18 months old WT femora. 
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Figure 3.3-11: Cortical width (Ct.Wi, µm) of mid-diaphyses of the right femora and right 
tibiae in GOAT KO and WT mice aged 6, 9 and 18 months. Statistical significance 
between means of GOAT KO and WTs was determined using independent Student’s t 
tests (GraphPad) and between the ages for each group using one-way ANOVA with 
Tukey’s post hoc analysis (GraphPad). Data represented as mean +/- standard error of 
the mean (SEM) significance accepted at p<0.05 and marginal significance accepted at 
p<0.1; a=p<0.05 compared to GOAT KO femora at same age, b=p<0.05 compared to 
GOAT-/- tibiae at same age, c=p<0.05 compared to 18 month WT femora, d=p<0.05 
compared to 18 month GOAT KO tibiae.  
 
 
60 
 
 
Ct.Wi in the femora of WT mice significantly increased with advancing age from 9 to 18 
months (p=0.01) (Figure 3.3-11). The Ct.Wi of the mid-diaphyses of the tibiae in GOAT-/- 
mice decreased with advancing age from 9 to 18 months (p=0.007) (Figure 3.3-11). 
 
The periosteal bone perimeter (Ps.Pm) is a measure of the periosteal circumference of 
the mid-diaphyses of long bones. It gives an indication of the bone formation occurring 
in the cortical bone during appositional growth in response to physiological changes. 
Ps.Pm was measured on the cross sectional images of the mid-diaphyses of tibiae or 
femora exported from the microCT scan from the Scanco µCT 40 desktop microCT 
scanner and imported to the Osteomeasure software. Contour lines were drawn around 
the cortical perimeter (circumference of the diaphysis) of the bone slice in the 
Osteomeasure software to generate the Ps.Pm values. Ps.Pm showed a significant 
increase with advancing age between 9 (8.62±0.39 mm) and 18 months (11.08±0.43 
mm; p=0.003) in the mid-diaphyses of tibiae in the GOAT-/- mice (Figure 3.3-12).  
 
The endosteal bone perimeter (Ec.pm) is a measure of the endosteal circumference of 
the mid-diaphyses of long bones. It gives an indication of the degree of bone resorption 
occurring on the endosteal surface of the cortical bone in response to physiological 
changes. Ec.Pm was measured on the cross sectional images of the mid-diaphyses of 
tibiae or femora exported from the microCT scan from the Scanco µCT 40 desktop 
microCT scanner and imported to the Osteomeasure software. Contour lines were 
drawn around the endosteal perimeter of the image in the Osteomeasure software to 
generate the Ec.Pm values. GOAT-/- mice showed significantly lower Ec.Pm at 6 
(p=0.02) and 18 (p=0.03) months of age (5.74±0.26 mm and 6.53±0.20 mm, 
respectively)of the mid-diaphyses of the femora compared to WT (6.67±0.19 mm and 
7.46±0.37 mm, respectively). GOAT-/- tibiae showed a significantly smaller Ec.Pm 
(p=0.002) of the mid-diaphyses compared to WT (6.53±0.26 mm) at 6 months of age 
(5.08±0.19 mm) (Figure 3.3-13). 
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Figure 3.3-12: Periosteal perimeter (Ps.Pm, mm) of the mid-diaphysis of right femora 
and right tibiae of GOAT KO and WT mice aged 6, 9 and 18 months. Statistical 
significance between means of GOAT KO and WTs was determined using independent 
Student’s t tests (GraphPad) and between the ages for each group using one-way 
ANOVA with Tukey’s post hoc analysis (GraphPad). Data represented as mean +/- 
standard error of the mean (SEM),significance accepted at p<0.05 and marginal 
significance accepted at p<0.1; a=p<0.05 compared to 9 month GOAT KO tibiae, b= 
p<0.05 compared to 18 month GOAT KO tibiae. 
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Figure 3.3-13: Endosteal perimeter (Ec.Pm, mm) of the mid-diaphyses of right femora 
and right tibiae of GOAT KO and WT mice aged 6, 9 and 18 months. Statistical 
significance between means of GOAT KO and WTs was determined using independent 
Student’s t tests (GraphPad) and between the ages for each group using one-way 
ANOVA with Tukey’s post hoc analysis (GraphPad). Data represented as mean +/- 
standard error of the mean (SEM), significance accepted at p<0.05 and marginal 
significance accepted at p<0.1; a= p<0.05 compared to GOAT KO femora at 6 months, 
b= p<0.1 compared to GOAT KO femora at 18 months, c= p<0.05 compared to GOAT 
KO tibiae at 6 months, d= p<0.05 compared to 18 month old GOAT KO femora, 
e=p<0.05 compared to 18 month old WT femora. 
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Figure 3.3-14: Cortical bone area (Ct.Ar, mm2) of the mid-diaphysis of right femora and 
right tibiae of GOAT KO and WT mice aged 6, 9 and 18 months. Statistical significance 
between means of GOAT-/- and WTs was determined using independent Student’s t 
tests (GraphPad) and between the ages for each group using one-way ANOVA with 
Tukey’s post hoc analysis (GraphPad). Data represented as mean +/- standard error of 
the mean (SEM), significance accepted at p<0.05 and marginal significance accepted at 
p<0.1; a=p<0.05 compared to GOAT KO femora at same age, b=p<0.05 compared to 
18 month old WT femora.  
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Ec.Pm of the femora in GOAT-/- mice significantly increased with advancing age from 6 
to 18 months (p=0.04), and Ec.Pm significantly increased with age in the femora of WT 
mice from 9 to 18 months (p=0.03).  
 
Cortical bone area (Ct.Ar) is the area of cortical bone occupying the mid-diaphyseal 
cross section. It is a similar measure to the Ct.Wi which provides information of the net 
of periosteal apposition and endosteal resorption occurring in the mid-diaphyses of the 
femora or tibiae. The Ct.Ar of the mid-diaphyses of GOAT-/- femora was significantly 
higher (p= 0.01) at 6 months (1.63±0.11 mm2) compared to WT femora (1.297±0.046). 
Similarly at 9 months the Ct.Ar of GOAT-/- femora (1.59±0.07 mm2) was significantly  
larger (p=0.02) than WT femora (1.32±0.06 mm2). With advancing age the Ct.Ar of the 
WT femora increased significantly from 9 (1.32±0.06 mm2) to 18 months (1.83±0.01 
mm2; p=0.0009). 
    
The polar moment of inertia (pMOI) is the distribution of bone around the longitudinal 
axis and is indicative of the bone’s ability to resist fracture under torsion loads. The 
calculation of pMOI (J= pi[radius of outer circle4 - radius of inner circle4]/2) of the mid-
diaphyses are based on the radius of the diaphyseal cross-sections (Bhavikatti and 
Rajashekarappa, 1994) and is reliant on the shape and size of the cylinder.  The pMOIs 
of the mid-diaphyses of the femora of GOAT-/- mice (0.51±0.03 mm4) were significantly 
lower at 18 months of age (p=0.025) compared to WT (0.69±0.07 mm4) (Figure 3.2-15) 
and the tibiae of GOAT-/- mice (0.28±0.02 mm4, 0.28±0.01 mm4 and 0.37±0.01 mm4, 
respectively) had significantly lower pMOI compared to WT (0.40±0.01 mm4  , 0.39±0.01 
mm4 and 0.43±0.01 mm4, respectively) at 6 (p=0.0006), 9 months (p=0.003) and 18 
months of age (p=0.028) (Figure 3.2-15). pMOI increased in the WT femora with 
advancing age from 9 (0.40±0.01 mm4) to 18 months (0.43±0.01 mm4; p=0.001) and 
also in the GOAT-/- femora from 9 (0.39±0.02 mm4) to 18 months (0.51±0.03 mm4; 
p=0.029) (Figure 3.3-15). The pMOI of GOAT-/- tibiae increased with advancing age 
from 9 (0.28±0.01 mm4) to 18 months (0.37±0.01 mm4; p=0.021) (Figure 3.3-15). 
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Figure 3.3-15: Polar moment of inertia (pMOI, mm4) of the mid-diaphysis of right femora 
and right tibiae of GOAT KO and WT mice aged 6, 9 and 18 months. Statistical 
significance between means of GOAT KO and WTs was determined using independent 
Student’s t tests (GraphPad) and between the ages for each group using one-way 
ANOVA with Tukey’s post hoc analysis (GraphPad). Data represented as mean +/- 
standard error of the mean (SEM), significance accepted at p<0.05 and marginal 
significance accepted at p<0.1; a=p <0.05 compared to GOAT KO femora at 18 months, 
b=p <0.05 compared to GOAT KO tibiae at same age, c=p <0.05 compared to 18 month 
WT femora, d= p <0.05 compared to 18 month GOAT KO femora, e=p <0.05 compared 
to 18 month GOAT KO tibiae. 
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4.3 Discussion 
 
In this study the trabecular and cortical bone microarchitecture of the femora and tibiae 
of female adult GOAT-/- mice aged 6, 9 and 18 months were characterised using high 
resolution µCT and is the first study to investigate and report the skeletal phenotype of 
GOAT-/- mice. The study found that the trabecular bone volume fraction of both femora 
and tibiae of GOAT-/- mice was significantly less at 6 months of age compared to the 
WT controls. There were no differences in the mineral density of the trabecular bone 
between the GOAT-/- and WT at 6 months. This suggests that the trabecular bone 
strength is reduced in the GOAT-/- femora and tibiae at 6 months via the volume of bone 
being reduced rather than reduced mineralisation. The reduced bone volume fraction in 
the GOAT-/- mice was due to less trabecular connectivity density in comparison to WT 
controls. Trabecular number, thickness and separation were not significantly different. 
Reduced connectivity density could be a result of a decrease in bone formation by 
osteoblasts relative to resorption by osteoclasts (Van Der Linden, Verhaar, & Weinans, 
2001) or an increase in osteoclast activity relative to osteoblast activity, resulting in 
incomplete filling of resorption cavities and focal perforations in the trabecular struts, 
similar to osteoporosis (Epstein, 2005). The lack of a change in the trabecular thickness 
suggests that the osteoblast activity is unchanged and the decrease in connectivity 
density is more likely a result of increased osteoclast activity in the GOAT-/- trabecular 
bone. GHSR-/- (partial lack of acyl ghrelin signalling) has been reported to increase 
osteoclastogenesis in culture, resulting in an increased pool of osteoclasts, without 
affecting osteoblastogenesis (van der Velde et al., 2012). In addition GHSR-/- mice 
showed increased osteoclast activity, demonstrated by a significantly higher osteoclast 
number on the trabecular bone surface at 6 months of age (van der Velde et al., 2012). 
The decrease in bone volume fraction in the GOAT-/- mice at 6 months of age is similar 
to the finding that the bone volume fraction of GHSR-/- mice is decreased at 6 months of 
age compared to WT controls (van der Velde et al., 2012). Although it was attempted to 
determine osteoclast activity through the osteoclast numbers on the trabecular bone 
surface of the GOAT-/- mice in this project, due to technical limitations and time 
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constraints we were unable to gather accurate and reliable data for osteoclast activity 
(see Appendix 6.2).  
 
The loss of trabecular bone volume fraction in the GHSR-/- mice, however, was a result 
of reduced trabecular number (loss of individual trabecular struts) (van der Velde et al., 
2012), whereas the reduced bone volume fraction in the femora and tibiae of GOAT-/- 
mice was due to less trabecular connectivity density in comparison to WT controls. 
Trabecular number, thickness and separation were not significantly different in the 
GOAT-/- femora or tibiae compared to WT. This suggests that the trabecular number 
may be unchanged in the GOAT-/- mice because the reduced connections may result in 
greater numbers of separate trabecular struts. The measurements were also taken in 
the femoral head for the GHSR-/- mice (van der Velde et al., 2012), whereas for the 
GOAT-/- mice in this study, the measurements were taken at the distal metaphyses of 
femora and proximal metaphyses of tibiae. Therefore, the loss of trabecular bone 
volume fraction resulting from loss of trabecular number or connectivity density may be 
site-specific.  
 
Acyl ghrelin function is mediated largely through GHSR1a (Kojima et al., 1999), 
however GHSR1a exhibits unusually high constitutive activity (Holst et al., 2003) and 
acyl ghrelin is capable of signalling in the absence of GHSR1a through alternative 
receptors (Caminos et al., 2005; Muccioli et al., 2004; Thielemans et al., 2007; Volante 
et al., 2003). GOAT is the enzyme responsible for the post-translational esterification of 
ghrelin to produce acylated ghrelin (Gutierrez et al., 2008; Yang et al., 2008) and GOAT-
/-
 mice are characterised by a total absence of acylated ghrelin, with the presence of 
desacyl ghrelin (Kirchner et al., 2009). The finding of this study that the trabecular bone 
volume fraction of GOAT-/- mice is reduced at 6 months was also seen in GHSR-/- mice 
(van der Velde et al., 2012) which had a reduced bone volume fraction at 6 months 
caused by increased osteoclast activity. This indicates that acyl ghrelin signalling 
through GHSR1a is responsible for the regulation of the trabecular bone 
microarchitecture through the regulation of bone metabolism. Lack of GHSR has shown 
an increase in osteoclast activity, suggesting that GHSR1a signalling may have an 
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inhibitory role on osteoclast activity (van der Velde, et al., 2012). Therefore, it is likely 
that the lack of acyl ghrelin signalling through GHSR1a in the GOAT-/- mice, may have 
increased osteoclast activity resulting in the similar observation of the reduced bone 
volume fraction.   
 
GOAT-/- mice aged 9 and 18 months were not significantly different in the bone volume 
fractions of the femora and tibiae compared to the WT controls of the same age. 
Surprisingly, GOAT-/- mice in these older age groups were heavier than the WT controls, 
potentially due to altered metabolism as the mice age, and this observation has not 
been published before. Alternatively, the increased weights of GOAT-/- mice in this study 
may be due to the older GOAT-/- mice being maintained in smaller numbers per cage 
due to their susceptibility to stress compared to the WTs (Jeffery, P., personal 
communication). The body compositions of the GOAT-/- were not investigated in this 
study, however a previous study has shown that older GOAT-/- mice have substantially 
higher initial body weights and fat mass (Yi et al., 2012).   
One of the major functions of trabecular bone is to support the ends of long bones in 
load bearing (Mow & Huiskes, 2005; Tanck, Homminga, van Lenthe & Huiskes, 2001). 
The increased weight of the GOAT-/- mice at 9 and 18 months would have increased the 
mechanical demands on the skeleton, leading to stimulation in bone formation within the 
trabecular compartment. This process is described by Frost’s mechanostat theory, 
which proposes that adaptive remodelling occurs when strains are above or below the 
physiological threshold of the animal (Ferretti, Capozza, Mondelo, & Zanchetta, 1993; 
Frost, 1990b). Although it would be expected that the GOAT-/- mice would have 
increased trabecular bone volume fraction due to the increased weights and therefore 
increased functional demand (Tanck, Homminga, van Lenthe, & Huiskes, 2001), this 
was not observed. The lack of difference in the trabecular bone volume fractions in the 
femora and tibiae between GOAT-/- and WT at 9 and 18 month of ages may have been 
due to an inhibition of osteoblast activity in the GOAT-/- mice, as ghrelin has positive 
effects on differentiation, proliferation and activity of osteoblasts (Costa et al., 2011; P. 
J. Delhanty et al., 2006; Fukushima et al., 2005; Kim et al., 2005; Liao L. & Wang, 2010; 
Maccarinelli et al., 2005). Conversely this observation may be due to the increased 
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osteoclast activity associated with ageing being unopposed in the absence of acyl 
ghrelin (van der Velde, et al., 2012), such that any stimulation in bone formation in the 
heavier animals may have been counteracted by increased bone resorption on the 
GOAT-/- trabecular bone surface.  
 
At 9 months of age the bone volume fraction did not show differences to the WT mice 
because the GOAT-/- maintained the trabecular number they showed at 6 months of age 
compared to the decline in trabecular number in the WT controls. Tb.N is computed as 
the inverse of the mean distance between the mid-axes of adjacent trabeculae 
(Bouxsein et al., 2010), therefore when the trabecular number is large, there is a high 
density of individual trabeculae within the volume of interest. A high Tb.N therefore may 
indicate a higher bone mass or that the trabeculae are distributed evenly across the 
volume of interest. A high Tb.N could also mean that the Tb.Th has increased resulting 
in a decreased distance between trabeculae and hence increased Tb.N. A smaller Tb.N 
can indicate that the trabeculae are far apart and therefore distance between mid-axes 
is large. This usually means that there are fewer connections between the trabeculae 
but not necessarily, such as in cases where only a very small amount of bone is 
remaining (Bouxsein et al., 2010)).  
 
At 9 months of age, the femora of GOAT-/- mice had higher Tb.N, smaller Tb.Th, smaller 
Tb.Sp, no difference in C.Den and no difference in BV/TV compared to WT. The high 
Tb.N of the GOAT-/- indicates that the trabeculae are more densely packed, and the low 
Tb.Sp indicates that there is less marrow space between adjacent trabeculae. These 
results alone would predict a higher BV/TV in the GOAT-/- mice at 9 months, however, 
this was not the case. Instead, no difference in BV/TV was observed between the 
GOAT-/- mice compared to WT mice at 9 months of age. Furthermore, in addition to the 
changes in trabeculae distribution, the Tb.Th was significantly lower in GOAT-/- mice. 
Therefore, whilst there was a higher density of trabeculae in the GOAT-/- mice, each 
trabecula was significantly thinner than WT mice, ultimately resulting in no change to 
bone volume. Bone remodelling through the tightly coupled activity between osteoclasts 
and osteoblasts affects the thickness of trabeculae. The reduced thickness indicates 
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that osteoclast activity is greater than osteoblast activity in the GOAT-/- mice in 
comparison to the WT mice. This suggests that osteoclast activity may be increased in 
the GOAT-/- mice similar to the increased osteoclast activity seen in the 6 month old 
GHSR-/- mice (van der Velde et al., 2012), suggesting that acyl ghrelin signalling 
through GHSR1a may be required for suppressing undesirable osteoclast activity at 
older ages.  
 
At 18 months of age, there were no differences in the BV/TV, Tb.N, Tb.Th, Tb.Sp and 
Conn.Den in the femora and tibiae of the GOAT-/- mice compared to WT mice. The bone 
volume fractions of GOAT-/- mice and WT mice at both 9 and 18 months of age 
appeared to be very small (approximately 2%). The lack of differences in morphometric 
parameters between the trabecular bone of GOAT-/- mice and WT mice at 18 months 
may be mainly attributed to the small amount of bone present in the volume of interest 
for comparison (Gregory, et al., 2006). 
 
The results of this study demonstrate distinctly different regulatory patterns in the 
cortical and trabecular bone compartments in the absence of GOAT. Cortical BMD 
generally decreases or remains unaltered with increasing age in adults (Flaherty, 1999; 
Furst, et al., 2008). The mineral density of the cortical bone of the mid-diaphyses of the 
femora and tibiae of GOAT-/- mice was higher at 6 and 9 months of age compared to 
WT mice. This indicates that the material property (hardness) of cortical bone which 
provides strength is enhanced in the absence of acyl ghrelin signalling, which suggests 
that acyl ghrelin signalling may contribute to age-related bone loss by reducing cortical 
bone density. 
   
The results of this study also demonstrate that the polar moment of inertia (pMOI) of 
cortical bone (geometric property of strength) in GOAT-/- mice is reduced. The reduced 
pMOIs were observed in the 18 month old femora and 6, 9 and 18 month old tibiae 
compared to WT controls. The GHSR-/- mice, however, have been reported to have a 
lower pMOI in the mid-shaft of the femora at 6 months of age (van der Velde, et al., 
2012). This indicates that at 6 months of age the absence of acyl ghrelin does not affect 
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the pMOI of femora, however, the absence of GHSR1a, which partly mediates acyl 
ghrelin signalling and has constitutive activity, reduces pMOI of femora. This suggests 
that the constitutive activity may play a modulatory role in providing strength to resist 
torsion in the femora at 6 months. The pMOI of tibiae, however, were reduced in the 
GOAT-/- mice at 6, 9 and 18 months of age compared to WT mice. This suggests that 
the modulation of strength to resist torsion in the mid-diaphyses by acyl ghrelin 
signalling may be limb-specific. Also, the changes observed in the GOAT-/- mice at 9 
and 18 months could be a result of increased weights in the GOAT-/- resulting in altered 
modelling.  
 
The periosteal perimeter of a cross-section of the mid-diaphyses of the femora and 
tibiae revealed that there were no differences between the periosteal perimeters 
between the GOAT-/- mice and WT mice. This indicates that the periosteal apposition 
(formation of bone on the periosteal surface by osteoblasts) was not affected by the 
absence of acyl ghrelin. The endosteal perimeter of a cross-section of the mid-
diaphyses of the femora and tibiae showed that the endosteal perimeter of GOAT-/- mice 
is reduced, in the femora at 6 and 18 months and in the tibiae at 6 months. This 
indicates that at 6 months the endocortical surfaces of the mid-diaphyses of femora and 
tibiae undergo less resorption. Therefore, this suggests that the osteoclast activity is 
regulated in a different manner (reduced osteoclast activity) during modelling in the mid-
diaphyses of cortical bone in comparison to remodelling in the trabecular bone 
(increased osteoclast activity).  It is unclear whether an endogenous modulator of 
cortical bone is different to the trabecular bone. For example, Tobias, et al., 
(1992) found opposite effects of insulin-like growth factor-I (IGF-I) on the formation of 
trabecular and cortical bone in adult female rats; IGF-I stimulated periosteal bone 
formation but reduced trabecular bone formation (Heap, et al., 2004). The results of our 
study also demonstrate that the cortical bone compartment regulation by acyl ghrelin is 
different to trabecular bone.   
 
Cortical width and cortical area in mid-diaphyses, showed an increase in femora of 
GOAT-/- mice at 6 and 9 months of age  compared to WT mice. The tibiae, however, 
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showed an increase in cortical width and not the cortical areas at 6 and 9 months of age 
in the GOAT-/- mice compared to WT. The increase of Ct.Wi and Ct.Ar in the femora at 6 
months is a result of smaller endosteal perimeters, however, at 9 months the increase in 
width could be a result of the adaptation to increased load in the GOAT-/- mice. It is 
unclear, the reason for the Ct.Wi and Ct.Ar difference in the tibiae at 6 and 9 months of 
age in the GOAT-/- mice. 
  
The regulation of bone metabolism by acyl ghrelin could be a result of the direct action 
of acyl ghrelin on osteoblasts and osteoclasts, or it could be indirect interactions with 
other hormones, or could be a combination of both direct and indirect mechanisms 
(Costa et al., 2011; P. J. Delhanty et al., 2006; Fukushima et al., 2005; Kim et al., 2005; 
Maccarinelli et al., 2005; van der Velde et al., 2012). One of the major functions of acyl 
ghrelin is the stimulation of growth hormone release (Kojima et al., 1999). Growth 
hormone is released in a pulsatile manner under the influence of environmental and 
physiological changes (Sattler, 2013). A current investigation carried out by Professor 
Chen Chen’s laboratory (University of Queensland) has shown that the pulsatile growth 
hormone levels of GOAT-/- mice aged 8 weeks are reduced compared to WT (Jeffery, 
P., personal communication). Growth hormone is a direct and indirect regulator of bone 
metabolism (Cannata et al., 2010; Giustina et al., 2008; Morel et al., 1993; Wit & 
Camacho-Hubner, 2011). Reduced pulsatile GH may reduce the pulsatility of other 
hormones necessary for bone metabolism, such as IGF-1 (Morel et al., 1993). As GH 
also acts directly on bone to regulate bone metabolism (Cannata, Vijayakumar, Fierz, & 
LeRoith, 2010), the long-term effect of reduced GH pulsatility might be related to the 
microarchitectural differences observed in the GOAT-/- mice, especially at 6 months of 
age in this study.  
 
In conclusion, this study demonstrates that the trabecular bone microarchitecture of 
bone of GOAT-/- mice aged 6 months has a decreased bone volume fraction as a result 
of decreased trabecular connectivity, indicating that acyl ghrelin is involved in the 
regulation of physiological bone remodelling by affecting the micro-structural properties 
of trabecular bone.. Reduced connectivity density may be a result of increased 
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osteoclast activity due to the lack of acyl ghrelin signalling as reported with GHSR-/- 
mice (van der Velde et al., 2012).  
The mid-diaphyses of the femora and tibiae of cortical bone of 6 month old GOAT-/- 
mice have increased mineralisation indicating that acyl ghrelin signalling may negatively 
regulate cortical bone mineralisation. The unaffected periosteal perimeters and reduced 
endosteal perimeters in the GOAT-/- mice aged 6 months, indicate that osteoclast 
activity may be reduced. The geometric property providing resistance to fracture by 
torsion (pMOI) is reduced in the tibiae at an ealier age compared to the femora in the 
GOAT-/- mice. These results suggest that acyl ghrelin signalling modulates cortical bone 
metabolism, and tibial cortical bone is affected earlier than femora. The results also 
indicate that cellular activity is regulated differently during bone remodelling in the 
trabecular bone compared to bone modelling in the cortical bone.  
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Chapter 4 
 
Expression of GHSR1a 
and GHR in chondrocytes 
of first trimester human 
fetal skeletons and mouse 
embryos 
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4.1 Introduction 
 
Bone formation during embryological development, juvenile growth and bone repair may 
occur via intramembranous ossification or endochondral ossification, or a combination 
of both (Cohen, 2006). The main difference between the two processes is that in 
endochondral ossification, a cartilage model is first formed which is then replaced by 
new bone tissue, whereas in intramembranous ossification in the embryo, bone is 
formed directly from mesenchyme without the intermediate cartilage model (Cohen, 
2006; Mackie et al., 2008; Olsen et al., 2000; Tuan, 2004). In endochondral ossification 
the behaviour of chondrocytes in the cartilage template is under the influence of a 
complex network of interactions between systemic and local endogenous signals such 
as growth hormone, insulin like growth factor-1, bone morphogenetic protein, fibroblast 
growth factors, thyroid hormone and parathyroid hormone (Mackie et al., 2008; Tuan, 
2004).  
 
Ghrelin has been reported to be expressed by chondrocytes (Caminos et al., 2005). 
Ghrelin (at the peptide level and mRNA transcript level) are expressed in mouse 
immortalised chondrocyte cell line (ATDC-5), juvenile human immortalised chondrocyte 
cell lines (T/C-28a2, C-20/A4 and C-28/I2) and rat epiphyseal growth plate 
chondrocytes (fetal and postnatal rats aged 1 day, 15 days and 25 days) (Caminos et 
al., 2005). The octanoylating enzyme, GOAT, is also expressed by cultured primary 
human chondrocytes (human articular cartilage derived), human immortalised 
chondrocyte cell lines (T/C-28a2 and C-28/I2) and immortalised mouse chondrocytes 
(ATDC-5) (Gomez et al., 2009). Although these reports indicate that acylated ghrelin is 
synthesised and secreted by chondrocytes, the study (Caminos et al., 2005) failed to 
identify GHSR1a mRNA in chondrocytes of the rat epiphyseal growth plates (fetal and 
postnatal rats aged 1 day, 15 days and 25 days) and human immortalised chondrocyte 
cell lines (T/C-28a2, C-20/A4 and C-28/I2). The analysis of 125-I ghrelin binding on 
human immortalised chondrocytes (T/C-28a2) however, suggested presence of 
alternative ghrelin binding receptors (Caminos et al., 2005). Ghrelin treatment also 
increased cAMP production and inhibited chondrocyte metabolic activity in human (T/C-
28a2) and mouse (ATDC-5) immortalised chondrocytes (Caminos et al., 2005). These 
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reports indicate that chondrocytes produce acylated ghrelin to signal through alternative 
receptors and modulate chondrocyte metabolism in the cartilage template for 
endochondral ossification. The failure to detect GHSR1a in chondrocytes is challenged 
by data on Geo Profiles in NCBI showing that human osteoarthritic chondrocytes in 
monolayer and matrix cultures express GHSR 
(http://www.ncbi.nlm.nih.gov/geoprofiles/67009914). These differences in results could 
be attributed to the different origins of the chondrocytes as well as detection methods. . 
Human fetal tissues including pancreas (Chanoine & Wong, 2004) and lung (Volante et 
al., 2002) express ghrelin and the GHSR1a, however, a major gap in the literature has 
been the lack of studies examining ghrelin and GHSR1a expression in human fetal 
chondrocytes. 
 
The growth hormone receptor (GHR) is expressed by chondrocytes of the costal 
cartilage of human fetuses in the second trimester and in infants between 3 and 8 
months (Werther, Haynes, Edmonson, et al., 1993; Werther, Haynes, & Waters, 1993; 
Werther et al., 1990) indicating a direct action of growth hormone (GH) in chondrification 
in human fetal development. The expression of the GHR has not been studied in human 
fetal skeletal sites of endochondral bone development such as vertebrae, and bones of 
upper and lower limbs, which may indicate whether GHR expression is widespread in 
the chondrocytes of the human fetal skeleton or just specific to the costal cartilage 
region. Furthermore, there have been no reports of the expression of the GHR in 
chondrocytes of the cartilage templates of the first trimester of human fetal skeletal 
development.   
 
The aim of this study was to investigate the expression of ghrelin, GHSR1a and GHR 
proteins in chondrocytes of first trimester human fetal primordial vertebrae, and the 
cartilage templates of the bones of the upper and lower limbs by immunohistochemistry. 
In addition, this study aimed to compare the expression of GHSR1a and GHR in 
chondrocytes of the cartilage templates of the first trimester human fetal skeleton 
cartilage templates to the chondrocytes of the cartilage templates of the mouse fetal 
skeleton.  
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4.2 Methods 
 
This study was carried out as detailed in Chapter 2 sections 2.5, 2.5.1 and 2.5.2. In 
brief, human fetal upper limbs, lower limbs and vertebral columns were harvested, fixed, 
processed, embedded and sectioned. The sections (n=5) of each tissue were 
immunostained for ghrelin, GHSR1a and GHR, using primary antibodies that have 
previously been validated using murine knockout tissues (Shin, et al., 2010; Fung, et al., 
2013). Chondrocyte morphology was determined on separate safranin O fast green 
stained sections to identify the chondrocytes on the immunostained sections. Mouse 
embryos aged E14.5, E16.5 and E18.5 were fixed, processed, embedded and 
sectioned. Sections (n=5) of each tissue were immunostained in a similar manner to the 
human tissue sections for the expression of GHSR1a and GHR. Sections were 
visualised under light microscopy and one section from each tissue was imaged for 
presentation. 
 
 
4.3 Results  
4.3.1 Morphology of the cartilage templates  
 
In order to identify the morphology of chondrocytes in cartilage templates, sections of 
human fetal vertebral column (Figure 4.3-1A), upper limb (Figure 4.3-1B) and lower limb 
(Figure 4.3-1C) were stained with safranin O fast green. The stained sections 
demonstrated the presence of proteoglycan-rich cartilage templates (stained pink) for 
endochondral bone formation. The chondrocytes were present in small cavities 
(lacunae) and were recognised as resting, proliferating or mature hypertrophic 
chondrocytes, based on their morphology. Resting chondrocytes were small individual 
cells present in lacunae, where more than one cell was present in a single lacuna these 
cells were characterising as proliferating cells and mature hypertrophic chondrocytes 
were characterised as gigantic cells present in swollen lacunae. The chondrocytes 
appeared to be arranged in distinct zones, particularly in the upper limb (Figure 4.3-1B) 
and lower limb (Figure 4.3-1C).  
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Figure 4.3-1: Human fetal tissues (7-10 weeks gestational age) vertebrae (A), upper 
limb (B) and lower limb (C) sectioned longitudinally and stained with safranin O fast 
green, magnification (100x), scale bar=500µm. Red stained tissue indicates cartilage 
(safranin O binding to proteoglycans) and green stained tissue indicates fibrous 
connective tissues. Note that three cellular zones based on morphological 
characteristics were present in each cartilage template (i) resting chondrocytes are 
indicated by R (seen as small individual cells in lacuna), (ii) proliferating chondrocytes 
are indicated by P (multiple cells in a single lacuna) and (iii) H indicates mature 
hypertrophic chondrocytes (enlarged giant sized cells in swollen lacuna).     
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Figure 4.3-2: Immunostaining for ghrelin expression in human tissues with rabbit polyclonal anti-
ghrelin antibody (Phoenix Pharmaceuticals Inc., H-031-31). Strong ghrelin immunoreactivity was 
present in the enteroendocrine cells of the positive control tissue (A), human adult stomach (arrow; 
400x). Ghrelin expression was not detected in human fetal (10-12 weeks) chondrocytes of the (B) 
lower limb (200x, arrow indicates resting chondrocyte) or upper limb. Similarly, (C) vertebral 
chondrocytes were non-immunoreactive for ghrelin (200x, arrow indicates hypertrophic 
chondrocyte). Negative controls included non-specific rabbit IgG on (D) upper limb (200x, arrow 
indicates proliferating chondrocyte) and omission of primary antibody. Scale bars are as shown. 
A 
C D 
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4.3.2 Expression of ghrelin, GHSR1a and GHR in human fetal cartilage 
 
Ghrelin immunoreactivity was not detectable in chondrocytes of first trimester human 
fetal tissue sections of the vertebral column (Figure 4.3-2C), upper limb (data not 
shown) and lower limb (Figure 4.3-2B). Positive control sections of human adult 
stomach immunostained for ghrelin expression demonstrated positive immunoreactivity 
with enteroendocrine ghrelin expressing cells indicating that the rabbit polyclonal anti-
ghrelin antibody (Phoenix Pharmaceuticals Inc., H-031-31) detected ghrelin. Negative 
control sections of human fetal upper limb immunostained with non-specific rabbit IgG 
(Figure 4.3-2D) showed no immunoreactivity with the tissue sections, indicating that the 
primary antibodies which were raised in rabbits did not immunoreact non-specifically 
with the tissue sections. 
 
Chondrocytes of the human fetal tissues were immunoreactive for GHSR1a. Human 
fetal tissue sections of vertebrae (Figure 4.3-3A and 4.3-3B), upper limb (Figure 4.3-3C) 
and lower limb (Figure 4.3-3D) immunostained for GHSR1a showed immunoreactivity 
with proliferating and hypertrophic chondrocytes of the cartilage templates. A lipid raft 
staining pattern was observed in the immunoreactive cells (Figure 4.3-2A). 
Immunoreactivity was not observed in resting chondrocytes of the cartilage templates. 
Positive control sections of mouse brain immunostained for GHSR1a expression 
demonstrated positive immunoreactivity with GHSR1a expressing cells indicating that 
the goat polyclonal anti-GHSR1a antibody (Santa Cruz Biotechnology, F-16) detected 
GHSR1a (data not shown). Negative control sections of human fetal upper limb 
immunostained with non-specific goat IgG (Figure 4.3-3 insert C) showed no 
immunoreactivity with the tissue sections indicating that the primary antibodies which 
were raised in goats did not immunoreact non-specifically with the tissue sections. 
 
GHR immunoreactivity was not detected in chondrocytes of first trimester human fetal 
tissues. Human fetal tissue sections of vertebrae (data not shown), upper limb (data not  
shown) and lower limb (Figure 4.3-4D) immunostained for GHR expression did not 
show immunoreactivity with chondrocytes of the cartilage templates. Positive control  
 
 
81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
50µm 
A B 
C D 
50µm 
E F G 
100µm 
 
 
82 
 
Figure 4.3-3: Human and murine fetal cartilage immunostained with goat polyclonal anti-
GHSR1a antibody (Santa Cruz Biotechnology, F-16). GHSR1a is expressed in the 
hypertrophic chondrocytes of human fetal (10-12 weeks gestational age) vertebrae (A, 
200x, scalebar= 500µm); insert shows a higher power image of A showing a lipid raft 
staining pattern (arrow) in some GHSR1a-positive chondrocytes (600x). (B) GHSR1a 
immunoreactivity in proliferating chondrocytes of fetal vertebrae (400x, scalebar= 50µm) 
and the hypertrophic chondrocytes of the (C) upper limb (arrow indicates hypertrophic 
region; 400x, scalebar= 50µm). Non-specific goat IgG negative control was non-
immunoreactive in the upper limb (insert; C). (D) The proliferative chondrocyte zone of 
the fetal knee was positive for GHSR1a expression (400x, scalebar= 50µm); not all cells 
are immunoreactive (insert; arrow indicates GHSR1a expressing cell). (E) Mouse 
embryo chondrocytes (E14.5) showed immunoreactivity for GHSR1a (400x, scalebar= 
50µm) as do (F) E16.5 chondrocytes (400x, scalebar= 50µm) and (G) E18.5 
chondrocytes (20x, scalebar= 50µm). 
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sections of mouse liver immunostained for GHR expression demonstrated positive 
immunoreactivity with GHR expressing cells indicating that the rabbit polyclonal growth 
hormone receptor antibody (Santa Cruz Biotechnology, H-300) detected GHR (Figure 
4.3-4A). Negative control sections of human fetal upper limb immunostained with non-
specific rabbit IgG (Figure 4.3-2D) showed no immunoreactivity with the tissue sections 
indicating that the primary antibodies which were raised in rabbits did not immunoreact 
non-specifically with the tissue sections. 
 
 
4.2.3 Expression of GHSR1a and GHR in mouse fetal cartilage 
 
GHSR1a immunoreactivity was detected in mouse fetal chondrocytes. E14.5 (Figure 
4.2.3E), E16.5 (Figure 4.2.3F) and E18.5 (Figure 4.2.3G) mouse fetal tissue sections 
immunostained for GHSR1a expression showed immunoreactivity with proliferating and 
hypertrophic chondrocytes of the cartilage templates. Immunoreactivity for GHSR1a 
was not observed in resting chondrocytes of the cartilage templates. 
  
GHR expression was detected in mouse fetal chondrocytes. E14.5 (Figure 4.2.4B and 
Figure 4.2.4C), E16.5 (data not shown) and E18.5 (data not shown) mouse fetal tissue 
sections immunostained for GHR expression showed immunoreactivity with proliferating 
and hypertrophic chondrocytes of the cartilage templates. Immunoreactivity was not 
observed in resting chondrocytes of the cartilage templates.  
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Figure 4.2-4: Murine and human fetal cartilage immunostained with rabbit polyclonal growth 
hormone receptor (GHR) antibody (Santa Cruz Biotechnology, H-300). (A) GHR is 
expressed in the nucleus of adult mouse liver hepatocytes (positive control; 400x). E14.5 
mouse chondrocytes demonstrating immunoreactivity for GHR in hypertrophic 
chondrocytes (B, 400x), (C) GHR is also expressed in the chondrocytes of the mouse 
embryo E16.5 (400x), GHR in hypertrophic chondrocytes (arrow). (D) Hypertrophic 
chondrocytes of mouse embryo (E18.5) stained for GHR (arrows; 400x) Human fetal (10-12 
weeks gestational age) lower limb chondrocytes (E) did not express GHR (200x). Scale 
bars are as shown. 
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4.3 Discussion 
 
This study demonstrates for the first time that GHSR1a is expressed by chondrocytes of 
the cartilage templates of vertebrae, and primitive upper and lower limbs of first 
trimester human fetal skeletons and the cartilage templates of mouse embryo/fetuses 
aged 14.5, 16.5 and 18.5 days post-conception. This finding contradicts the conclusion 
by Caminos et al., (2005), which failed to detect GHSR1a in rat and human 
immortalised chondrocytes by RT-PCR and concluded that GHSR1a is not expressed 
by chondrocytes. In addition to immunohistochemical identification of GHSR1a, we have 
identified GHSR1a mRNA transcript expression using quantitative RT-PCR in 
chondrocytes which have been differentiated from human fetal mesenchymal stem cells 
(personal communication, P Jeffery). In the present study the antibody that was used to 
detect GHSR1a has been validated and does not show non-specific binding in GHSR 
knockout mouse tissues (Shin et al., 2010) or GHSR knockout human cells (Fung et al., 
2013). We have also demonstrated that this antibody specifically detect GHSR1a in 
mouse brain. GHSR1a expression may also be species or cell type specific, as this 
study shows the expression of GHSR1a in chondrocytes of human and mouse. In 
contrast, Caminos et al., (2005) investigated expression in rat chondrocytes and 
immortalised human chondrocytes. We detected GHSR1a in cells showing 
morphological features of proliferation and hypertrophy, and expression was not seen in 
resting chondrocytes. The different cartilage cell types should be confirmed, however, 
using immunohistochemical markers such as SOX-9, Col2a and Agc1. Chondrocyte 
proliferation and maturation are the two drivers of cartilage tissue elongation (Mills, 
2012).This suggest that GHSR1a activation may be responsible for chondrocyte 
proliferation and maturation in the cartilage templates that may result in cartilage 
growth. Hypertrophic chondrocytes synthesise vascular endothelial growth factors, and 
therefore could allow the invasion of blood vessels (Ferrara, et al., 2003). Blood vessel 
infiltration facilitates the degradation of the cartilage matrix by circulating osteoclasts 
and subsequent ossification (Karsenty, 1999). Therefore, expression of GHSR1a in 
hypertrophic chondrocytes suggests that GHSR1a activation may lead to endochondral 
ossification in addition to cartilage growth.  
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The endogenous ligand for GHSR1a is acylated ghrelin (Kojima et al., 1999), however, 
ghrelin expression was not detected in the chondrocytes in vertebrae and primitive 
upper and lower limbs of the human fetal tissues. Unlike Caminos et al., 2005, we could 
not detect ghrelin expression by the chondrocytes of the human fetal cartilage 
templates. This may be because of the different antibodies used for the different 
studies, but also may be because we investigated human chondrocytes whereas 
Caminos, et al., 2005 investigated rat chondrocytes. This suggests that an 
autocrine/paracrine ghrelin signalling pathway may be absent in human fetal cartilage 
templates. Ghrelin, however, is produced by fetal tissues (and the main source is the 
pancreas at this stage of development) (Chanoine & Wong, 2004; Wierup, Svensson, 
Mulder, & Sundler, 2002) and maternal ghrelin crosses the placenta (Nakahara et al., 
2006) to be present in abundance to activate GHSR1a in chondrocytes by endocrine 
signalling. GHSR1a is a constitutively active receptor (Holst et al., 2003), therefore, 
GHSR1a may have a constitutive and ligand stimulated activity in chondrocytes.  
 
Furthermore, most chondrocytes displayed a lipid raft staining pattern. Lipid rafts are 
plasma membrane micro-domains that are implicated in the assembly of diverse 
signalling pathways such as those mediated by growth factors (Simons and Toombre, 
2000). The aggregated GHSR1a staining pattern that was observed in a small region of 
the chondrocyte, is characteristic of a lipid raft (Gupta and DeFranco, 2003) and  
indicates that GHSR1a may be activated and signal transduction is occurring. Caminos 
et al., (2005) showed that ghrelin treatment increased cAMP production and inhibited 
chondrocyte metabolic activity in human (T/C-28a2) and mouse (ATDC-5) immortalised 
chondrocytes, which do not express GHSR1a (Caminos et al., 2005). GHSR1a 
activation may lead to similar observations in human and mouse chondrocytes, 
however, further investigation is required to confirm the role of GHSR1a activation in 
human and mouse chondrocytes. 
 
A direct action of GH on human fetal chondrocytes has been indicated due to the 
expression of GHR in second trimester human fetal chondrocytes (Werther, Haynes, 
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Edmonson, et al., 1993; Werther, Haynes, & Waters, 1993; Werther et al., 1990). A 
major function of ghrelin is the stimulation of GH release. Therefore, this study 
investigated GHR expression in the first trimester human fetal chondrocytes. This study 
showed that GHR is not expressed by chondrocytes of the first trimester human fetal 
upper limbs, lower limbs and vertebrae, however, GHR is expressed by proliferating and 
mature chondrocytes of mouse fetuses aged 14.5, 16.5 and 18.5 days post-conception. 
Previous studies have shown that GHR is expressed by human fetal chondrocytes in 
the second trimester of pregnancy (Werther, Haynes, Edmonson, et al., 1993; Werther, 
Haynes, & Waters, 1993; Werther et al., 1990). Therefore, GHR may not be expressed 
until the second trimester of gestation. The standardised system of classifying the 
stages of gestation in the mouse compared to the human is the Carnegie system, 
however, this system only classifies the embryonic stage and is divided into 23 stages, 
which corresponds to day 58 post conception (stage 23) in humans (O’Rahilly & Müller, 
1897) and 16 days post conception (stage 23) in mice (day 58 corresponding to mouse 
day 16 post-conception). Similarly, the Theiler and the Downs and Davies stages 
classification systems reflect how far the human and mouse embryos have progressed 
in their development (Downs & Davies, 1993; Goryanin & Goryachev, 2012). There is 
no classification system that relates the trimesters or stages of skeletal development 
and ossification of human gestation to mouse. The mouse fetuses used in this project 
were at late stages of pregnancy (E14.5, E16.5 and E18.5), and therefore GHR and 
GHSR1a expression may not be comparable to human chondrocytes of the first 
trimester. In addition, expression is likely to be species-specific. Identification of 
signalling receptors, and elucidating their function and mechanism of action, provides 
opportunities for therapeutic targeting. This study has shown that GHSR1a is expressed 
by human fetal chondrocytes in the first trimester of human pregnancy, a stage at which 
GHR is not expressed. This provides an opportunity to investigate therapeutical 
targeting of GHSR1a, such as down-regulation with inverse agonists or stimulation with 
ghrelin mimetics, for disorders of skeletal development, such as skeletal dysplasias in 
animal models.  
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In conclusion, this study has shown for the first time that GHSR1a is expressed by first 
trimester human fetal chondrocytes and mouse embryo/ fetal chondrocytes. 
Furthermore, we have shown that human fetal chondrocytes in the first trimester of 
pregnancy do not express ghrelin and GHR, indicating that an autocrine/ paracrine 
signalling pathway through GHSR1a may be absent. Direct growth hormone signalling 
is not involved in the modulation of behaviour of chondrocytes of first trimester cartilage 
templates.  
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Chapter 5 
 
General Discussion and 
Future Directions 
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5.1 Discussion and future directions: characterisation of the bone micro-
architecture of GOAT-/- mice. 
 
The ghrelin axis appears to have direct and indirect regulatory effects on the bone and 
cartilage microenvironments (Caminos, et al., 2005; Delhanty, et al., 2013; Fukushima, 
et al., 2005; Kim, et al., 2005; van der Velde, et al., 2012). Positive correlations have 
been observed between ghrelin levels and bone mineral density (BMD) in several 
human populations ((Amini et al., 2013; Misra et al., 2005; Napoli et al., 2011; Nouh et 
al., 2012; Oh et al., 2005; Weiss et al., 2006), and administration of ghrelin increases 
BMD in rodents (Fukushima, et al., 2005). Ghrelin receptor (GHSR1a) knockout (GHSR-
/-) mice have shown significantly weaker bone micro-architectures with ageing due to 
increased osteoclast activity (van der Velde, et al., 2012). As GHSR1a only partly 
mediates acyl ghrelin signalling, the first part of this project characterised the 3D bone 
microarchitecture of adult GOAT-/- mice, which do not produce the acylated form of 
ghrelin. This was done in order to confirm whether acyl ghrelin signalling is critical for 
age-related maintainence of bone microarchitecture.  This study demonstrated that the 
trabecular bone microarchitecture of GOAT-/- mice aged 6 months has a decreased 
bone volume fraction as a result of decreased trabecular connectivity. No difference in 
BMD was observed, indicating that acyl ghrelin is involved in the regulation of 
physiological bone remodelling affecting the trabecular microarchitecture. Reduced 
connectivity density may be a result of increased osteoclast activity due to the lack of 
acyl ghrelin signalling as reported with GHSR-/- mice (van der Velde et al., 2012). Due to 
time constraints and technical limitations, we could not reliably measure osteoclast 
numbers on the trabecular bone surface. Therefore, as a future direction, it is 
recommended that the resorption pits on the trabecular bone surface on 2D resin 
sections of the GOAT-/- and WT mice are measured, to determine whether osteoclast 
activity is affected by the lack of acyl ghrelin.   
  
The mid-diaphyses of the femora and tibiae of cortical bone of 6 month old GOAT-/- 
mice had increased mineralisation indicating that acyl ghrelin signalling may negatively 
regulate cortical bone mineralisation. The periosteal perimeters were unaffected and 
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endosteal perimeters were reduced in the GOAT-/- mice aged 6 months, indicating that 
osteoclast activity may be reduced. Further work is needed to evaluate osteoclast 
activity through the measurement of resorption pits, in the endosteal perimeter of 
femora and tibiae of GOAT-/- and WT mice. This will provide information on how 
osteoclast activity during bone modelling is affected by the lack of acyl ghrelin 
signalling. The geometric property providing resistance to fracture by torsion (pMOI) 
was reduced in the tibiae at an earlier age compared to the femora in the GOAT-/- mice. 
The results suggested that acyl ghrelin signalling modulates cortical bone metabolism, 
and tibial cortical bone is affected earlier than femora. The results also indicated that 
cellular activity is regulated differently during bone remodelling in the trabecular bone 
compared to bone modelling in the cortical bone. As remodelling is a tightly coupled 
activity between osteoclasts and osteoblasts (Sebba, 2013), we also recommend 
evaluating osteoblast activity on the trabecular bone through dynamic 
histomorphometry. The microarchitecture of the youngest adult GOAT-/- mouse (6 
months old) used in this investigation showed a significant differences in trabecular and 
cortical bone compared to WT mice. Therefore, it would be ideal to investigate whether 
GOAT KO mice have less bone throughout lifespan or whether they also go through an 
age-related bone loss, similar to GHSR-/- mice. We recommend further work 
characterising the microarchitecture of younger GOAT-/- mice, such as neonatal and 8 
week old mice. 
 
We also characterised trabecular and cortical bone microarchitectures of 9 and 18 
month old GOAT-/- mice, however, the limitation comparing GOAT-/- mice to WT mice 
was that the GOAT-/- mice were heavier at these ages. potentially due to deranged 
metabolic activity with age. Alternatively, the greater weights may be a result of the 
older GOAT-/- mice being maintained with smaller numbers per cage due to their 
increased susceptibility to stress compared to WT mice (Jeffery, P., personal 
communication). As increased strain resulting from increased weight causes adaptive 
bone remodelling and modelling in bone tissue (Ferretti et al., 1993; Frost, 1990b), the 
differences between 9 and 18 month old GOAT-/- mice and WT mice may have been 
compromised. If it would be possible to have matched weights of the GOAT-/- to WT in 
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the future, further work may be carried out to investigate the impact of the lack of acyl 
ghrelin on bone in aged mice. In addition, due to the interaction of acyl ghrelin with other 
hormones, such as growth hormone, it is also possible that compensatory pathways 
may exist that may result in indirect effects on the GOAT-/- bones. Although it was 
attempted in this project to determine the expression of ghrelin, GHSR1a and GOAT in 
osteoblasts and osteoclasts in the paraffin embedded sections by 
immunohistochemistry, we could not optimise the protocol. Therefore, further attempts 
on optimising the protocol may provide information on whether acyl ghrelin acts in an 
autocrine/paracrine signalling pathway and whether it directly affects osteoblast and 
osteoclast activity.  
 
      
5.2: Discussion and future directions: GHSR1a and GHR in chondrocytes 
 
The ghrelin axis has been indicated to play a role in cartilage metabolism. Rat 
chondrocytes and human immortalised chondrocytes have been shown to express 
ghrelin, but lack GHSR1a (Caminos, et al., 2005). In this part of the project, we 
investigated whether ghrelin and GHSR1a is expressed by chondrocytes of the first 
trimester human fetal skeleton and mouse embryos and fetuses. Immunohistochemistry 
was performed on sections of first trimester human fetal upper limbs, lower limbs and 
vertebral columns, and mouse embryos and fetuses aged 14.5, 16.5 and 18.5 days 
post-conception, for the expression of ghrelin and GHSR1a. Ghrelin immunoreactivity 
was not seen in the chondrocytes of the first trimester human fetal upper limbs, lower 
limbs and vertebrae. This suggests that an autocrine/ paracrine ghrelin signalling 
pathway may be absent in the human cartilage microenvironment, however, ghrelin is 
expressed by many fetal tissues and maternal ghrelin also crosses the placenta to 
signal in an endocrine manner. Alternatively, due to very low expression levels, the 
ghrelin antibody concentration might have been too low to detect ghrelin in the 
chondrocytes. Therefore, we recommend as a future direction to investigate ghrelin 
expression in the cartilage templates using higher concentration of the ghrelin primary 
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antibody or using use an anti-ghrelin antibody that is species-specific, and/or investigate 
an alternative methodology such as Western immunoblot. 
Furthermore, due to time constraints with the project it was only possible to perform 
immunohistochemistry for ghrelin expression on human fetal chondrocytes. Therefore, 
as a future direction we recommend investigating ghrelin expression by 
immunohistochemistry on the mouse fetal chondrocytes. GHSR1a immunoreactivity 
was seen in the chondrocytes of the first trimester human fetal upper limbs, lower limbs 
and vertebrae, and mouse embryos/ fetuses aged E14.5, E16.5 and E18.5. 
Immunoreactivity was seen in proliferating and mature hypertrophic chondrocytes, and 
expression was not seen on resting chondrocytes of human vertebral columns, upper 
limbs and lower limbs, and mouse embryos/ fetuses. Even though, we identified 
chondrocytes based on their morphology, we recommend confirming the cells 
expressing GHSR1a are indeed chondrocytes and their proliferation, differentiation and 
maturation state, by immunohistochemical investigation using specific markers such as 
SOX-9, Col2a and Agc1. We recommend a future study to investigate GHSR1a 
activation by acyl ghrelin in chondrocytes expressing GHSR1a in culture to determine 
the effect on proliferation and maturation. This will provide information of the role 
GHSR1a activation may have on chondrocytes and elucidate the function of ghrelin and 
GHSR1a on cartilage homeostasis. 
 
Furthermore, ghrelin is associated with GH release (Kojima, et al., 1999). GH mediates 
its function through GHR (DiGirolamo et al., 2007) and GHR has been reported to be 
expressed by second trimester human fetal chondrocytes (Werther, Haynes, 
Edmonson, et al., 1993; Werther, Haynes, & Waters, 1993; Werther et al., 1990). 
Therefore, in this project we further investigated whether GHR is expressed by first 
trimester human fetal chondrocytes to determine whether ghrelin may be indirectly 
linked to cartilage metabolism. GHR was not expressed by the first trimester human 
fetal chondrocytes of the upper limb, lower limb and vertebral column, however, 
expression was seen in proliferating and mature chondrocytes of mouse embryos/ 
fetuses. Further investigation is required to determine the degree of skeletal 
development or stage of chondrification/ossification of limb buds of the human fetuses 
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and mouse embryos/fetuses to relate GHR expression on human fetal chondrocytes to 
the mouse fetal chondrocytes. Furthermore, mouse embryos at an earlier age could be 
investigated for GHR expression that may relate to the first trimester human fetus.  
 
In conclusion, this project provides preliminary evidence for a role of the ghrelin axis in 
bone and cartilage metabolism. This study has shown for the first time that GHSR1a is 
expressed by first trimester human fetal chondrocytes and mouse embryo/ fetal 
chondrocytes. Furthermore, we have shown that human fetal chondrocytes in the first 
trimester of pregnancy do not express ghrelin and GHR, indicating that an autocrine/ 
paracrine signalling pathway through GHSR1a may be absent. Direct growth hormone 
signalling is not involved in the modulation of behaviour of chondrocytes of first trimester 
cartilage templates. This study demonstrates that the trabecular bone microarchitecture 
of bone of GOAT-/- mice aged 6 months has a decreased bone volume fraction as a 
result of decreased trabecular connectivity, indicating that acyl ghrelin is involved in the 
regulation of physiological bone remodelling by affecting the micro-structural properties 
of trabecular bone.. Reduced connectivity density may be a result of increased 
osteoclast activity due to the lack of acyl ghrelin signalling as reported with GHSR-/- 
mice (van der Velde et al., 2012).  
The mid-diaphyses of the femora and tibiae of cortical bone of 6 month old GOAT-/- 
mice have increased mineralisation indicating that acyl ghrelin signalling may negatively 
regulate cortical bone mineralisation. The unaffected periosteal perimeters and reduced 
endosteal perimeters in the GOAT-/- mice aged 6 months, indicate that osteoclast 
activity may be reduced. The geometric property providing resistance to fracture by 
torsion (pMOI) is reduced in the tibiae at an ealier age compared to the femora in the 
GOAT-/- mice. These results suggest that acyl ghrelin signalling modulates cortical bone 
metabolism, and tibial cortical bone is affected earlier than femora. The results also 
indicate that cellular activity is regulated differently during bone remodelling in the 
trabecular bone compared to bone modelling in the cortical bone.  
This study offers supporting evidence for exciting new research opportunities for the 
ghrelin axis to be investigated for the treatment and management of a wide range of 
bone and cartilage related disorders. 
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6.1 Limb lengths of the GOAT-/- and WT mice 
The lengths of the femora and tibiae harvested from each mouse aged 6 and 9 months 
were measured to check whether lack of ghrelin signalling may have any effect on 
longitudinal growth. The right tibiae of GOAT-/- mice were significantly shorter (p=0.002) 
than the WT tibiae. The length of the GOAT-/- right tibiae increased significantly with 
advancing age from 6 to 9 months (p=0.017). The left and right femora did not show any 
differences between the GOAT-/- mice and WT mice at any ages, neither did the left 
tibiae (Figure 6.1-1).  
 
 
6.2 Evaluation of osteoclast activity 
Osteoclast numbers on the bone surface of the secondary spongiosa of the left femora 
and tibiae of GOAT-/- and WT mice aged 6, 9 and 18 months were determined following 
TRAP staining of paraffin embedded sections, using the Osteomeasure program. The 
osteoclast number on the bone surface did not show any significant differences at any 
ages or with advancing age. The sample sizes were uneven for each group, as there 
were damages to tissue sections during tissue processing and staining. The drawbacks 
of the measurements were that it was carried out only on 1 section per mouse, the bone 
volume in the section was not representative of the bone volume measured by micro-
CT, the volume of bone and osteoclast numbers varied greatly between each group as 
a result of the variation in the amount of bone of each section. Therefore, as future 
work, sections of right femora and tibiae representing the amount of bone determined 
by micro-CT should be used for evaluating the osteoclast activity. 
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Figure 6.1-1 Lengths of the femora and tibiae of the GOAT-/- and WT mice of the a) right 
limb and b) left limb. Statistical significance between mean length of GOAT-/- and WTs 
was determined using independent t tests (GraphPad) and between the ages for each 
group using one-way ANOVA with Tukey’s post hoc analysis (GraphPad). Data 
represented as mean +/- standard error of the mean (SEM); a=p<0.05 compared to 
GOAT KO right tibiae at 6 months of age, b=p<0.05 compared to GOAT KO right tibiae 
at 9 months. 
 
 
  
Figure 6.2-1 Osteoclast numbers on the surface of trabecular bone in the secondary 
spongiosa of the femora and tibiae between GOAT-/- and WT mice aged 6, 9 and 18 
months. Osteoclasts were identified as pink stained cells on the surface of trabecular 
bone and quantified using Osteomeasure. Statistical significance between means of 
GOAT-/- and WTs was determined using independent Student’s t tests (GraphPad) and 
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between the ages for each group using one-way ANOVA with Tukey’s post hoc analysis 
(GraphPad). Data represented as mean +/- standard error of the mean (SEM); The  
 
6.3 Immunohistochemistry for ghrelin, GOAT, GHSR1a, osteocalcin and runx2 in 
WT neonatal and 8 week old left tibia paraffin embedded sections  
Immunohistochemistry was performed for the expression of ghrelin, GOAT, GHSR1a, 
osteocalcin and runx2 as described in chapter 2, 2.4.1. The primary ghrelin antibody 
(rabbit polyclonal anti- mouse ghrelin,Phoenix Pharmaceuticals Inc., H-031-31) could 
not be optimised as it immunoreacted non-specifically with marrow components. 
Dilutions of 1:100, 1:500 and 1:1000 were tested and all showed same response. 
The primary GOAT antibodies (goat anti-human GOAT antibody, Abcam, ab-170690, 
goat anti-human MBOAT4 antibody, Santa Cruz Biotechnology, sc-98001), were used 
at dilutions of 1:100, 1:500 and 1:1000. The antibodies immunoreacted with GOAT 
knockout stomach tissues, indicating the antibodies were non-specific for detecting 
GOAT. 
The primary GHSR1a antibody (goat polyclonal anti-human GHSR1a, Santa Cruz 
Biotechnology, F-16) bound non-specifically to the marrow components of the neonatal 
and 8 week old WT sections at concentrations of 1:100, 1:200 and 1:500. The 
osteocalcin (anti-human osteocalcin, Santa Cruz Biotechnology, sczsc-30044) and 
runx-2 antibodies (anti-human runx2 antibody, Abcam, ab23981) did not show any 
immunoreactivity with the sections. 
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Figure 6.3-1. Neonatal section immunostained for GOAT at 1:1000 (Abcam, ab-
170690). Non-specific immunoreactivity, brown staining on non-cellular background of 
marrow, antibody does not detect GOAT specifically. Magnification=  x400, scalebar as 
shown. 
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Figure 6.3-2. GOAT-/- mouse stomach section immunostained for GOAT at 1:1000 
(Abcam, ab-170690). Brown staining of cells that do not express GOAT. Non-specific 
immunoreactivity seen. Magnification= x400, scalebar as shown. 
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6.4 Tables of results 
Table 6.4-1: Weights of GOAT-/- and WT mice aged 6, 9 and 18 months. Values given 
as mean± standard error of mean (SEM), p values determined by Students t test.  
Age (months) 
 6 9 18 
 
Weight 
(g) 
GOAT-/- 28.14±2.88 38.76 ±2.28 36.15 ±0.85  
 WT 27.47 ±0.58 28.94±0.26 32.3±1.36 
p 0.7709 0.0027 0.0317 
 
 
 
Table 6.4-2: Trabecular micro-architectural indices of the secondary spongiosa of the 
right distal femoral metaphysis and right proximal tibial metaphysis measured by micro-
CT, between the GOAT-/- and WT mice aged 6, 9 and 18 months. Values given as 
mean± standard error of mean (SEM), p values determined by Students t test. 
Age (months) 
 
6 9 18 
Limb Femur Tibia Femur Tibia Femur Tibia 
Tb. BMD 
(mgHA/cm3) 
GOAT-/- 880.28 
±6.15 
879.61
±16.8 
896.92
±9.82 
941.80
±8.63 
921.01±
20.69 
941.87±
48.84 
WT 864.05
±12.58 
918.21
±8.164 
877.61
±11.53 
 
922.21
±13.73 
 
947.88±
26.86 
 
957.34±
9.95 
p 0.332 0.100 0.240 0.295 0.451 0.737 
BV/TV (%) GOAT-/- 3.1 
±0.5 
1.68 
±0.2 
2.76 
±0.4 
2.14 
±0.4 
 
1.81 
±0.5 
1.38 
±0.2 
WT 6.2 
±0.6 
6.3 
±1.2 
3.0 
±0.8 
2.3 
±0.8 
 
2.3 ±0.9 1.9 ±0.7 
p 0.005 0.007 0.713 0.903 0.670 0.481 
Tb. N (1/mm) GOAT-/- 2.02 
±0.16 
1.91 
±0.18 
2.02 
±0.11 
1.50 
±0.21 
1.43 
±0.12 
0.96 
 ±0.12 
WT 2.25 
±0.27 
2.13 
±0.351
08 
1.32 
±0.14 
1.03 
±0.09 
 
1.46 
±0.18 
1.29 
±0.14 
p 0.538 .634 0.006 0.102 0.903 0.140 
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Tb. Th (mm) GOAT-/- 0.058 
±0.004 
0.056 
±0.003 
0.053 
±0.002 
0.058 
±0.004 
0.053 
±0.005 
 
0.056 
±0.001 
WT 0.062 
±0.003 
0.059 
±0.002 
 
0.065 
±0.002 
0.067 
±0.002 
0.067 
±0.003 
0.066 
±0.003 
p 0.427 0.391 0.001 0.094 0.120 0.022 
Tb.Sp (mm) GOAT-/- 0.51 
±0.05 
0.46 
±0.04 
0.49 
±0.02 
0.71 
±0.09 
0.73 
±0.05 
1.09 
±0.11 
WT 0.48 
±0.05 
0.53 
±0.06 
0.85 
±0.12 
1.02 
±0.09 
0.72 
±0.10 
0.81 
±0.08 
p 0.698 0.468 0.017 0.053 0.880 0.108 
C. Den (1/mm3) GOAT-/- 6.20 
±0.83 
 
0.85 
±0.34 
 
7.04 
±1.37 
2.12 
±0.71 
3.58 
±1.36 
1.18 
±0.61  
 WT 23.06 
±5.89 
26.61 
±10.23
4 
7.99 
±2.84 
2.35 
±1.78 
2.30 
±2.01 
2.78 
±1.93 
 p 0.039 0.062 0.757 0.902 0.598 0.411 
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Table 6.4-3: Cortical micro-architectural indices of the mid-diaphyses of the right femora 
and right tibia measured by micro-CT and Osteomeasure, between the GOAT-/- and WT 
mice aged 6, 9 and 18 months. Values given as mean± standard error of mean (SEM), 
p values determined by Students t test. 
 
 
    Age     (months) 6  9  18  
Limb Femur Tibia Femur Tibia Femur Tibia 
Ct. BMD 
(mgHA/cm3) 
 
GOAT-/- 1208.99
±17.61 
1176.26 
±10.98 
1241.22 
±14.33 
1175.50 
±5.31 
1243.86 
±7.48 
1168.62 
±4.56 
WT 1155.15 
±16.33 
 
1116.57
±22.24 
 
1197.81 
±8.77 
 
1132.45 
±2.55 
 
1238.3 
±16.80 
 
1152.61 
±20.80 
 p 0.055 0.042 0.046 0.0003 0.733 0.384 
 
Ct.Th (µm) 
GOAT-/- 240.79 
±15.84 
202.17 
±5.66 
222.57 
±6.53 
202.97 
±3.01 
216.86±1
3.75 
176.21 
±4.50 
WT 174.99 
±7.17 
 
168.24 
±8.63 
 
179.22 
±7.28 
 
166.03 
±8.47 
 
222.00 
±10.42 
 
165.32 
±13.56 
 p 0.005 0.011 0.003 0.002 0.803 0.394 
Ps. Pm (mm) 
 
GOAT-/- 7.77 
±0.21 
8.45 
±0.44 
8.27 
±0.25 
8.62 
±0.38 
8.40 
±0.28 
11.08 
±0.43 
WT 8.171 
±0.16 
 
9.67 
±0.48 
 
8.34 
±0.27 
 
9.20 
±0.11 
 
8.58 
±0.05 
 
10.36 
±0.43 
 p 0.180 0.103 0.852 0.242 0.691 0.295 
Ec. Pm (mm) 
 
GOAT-/- 5.74 
±0.26 
5.08 
±0.19 
6.06 
±0.15 
5.51 
±0.62 
6.53 
±0.20 
5.95 
±0.36 
WT 6.67 
±0.19 
 
6.53 
±0.26 
 
6.37 
±0.15 
 
6.02 
±0.20 
 
7.46 
±0.37 
 
6.17 
±0.54 
 p 0.021 0.002 0.209 0.515 0.039 0.732 
Ct.Ar (mm2) 
 
GOAT-/- 3.11 
±0.08 
2.22 
±0.10 
3.18 
±0.08 
2.31 
±0.19 
3.82 
±0.14 
2.89 
±0.27 
WT 3.28 
±0.02 
 
2.440 
±0.06 
 
3.392 
±0.09 
 
2.368 
±0.06 
 
4.226 
±0.17 
 
2.51 
±0.05 
 p 0.071 0.122 0.135 0.825 0.118 0.271 
pMOI 
 
GOAT-/- 0.40 
±0.03 
 
0.28 
±0.02 
 
0.39 
±0.02 
 
0.28 
±0.01 
 
0.51 
±0.03 
 
0.37 
±0.01 
 WT 0.37 
±0.008 
 
0.40 
±0.017 
 
0.40 
±0.021 
 
0.39 
±0.015 
 
0.69 
±0.07 
 
0.436 
±0.010 
 p 0.4273 0.0062 0.8663 0.0032 
 
0.0260 0.0287 
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Table 6.4-4: Micro-architectural indices of 8 week old female (non-pregnant) WT mice, 
characterised for comparison with 8 week old GOAT-/- mice. 
 
8 week old WT 
limb femora  tibiae 
Tb. BMD 
(mg/HAcm3) 
97.28±10.8 90.99±11.69 
BV/TV (%) 8.27±1.36 9.85±1.65 
Tb.N (1/mm) 4.22±0.19 3.81±0.29 
Tb.Th (mm) 0.049±0.001 0.049±0.001 
Tb.Sp (mm) 0.235±0.01 0.269±0.021 
Conn.Den (1/mm3) 73.47±14.72 65.92±17.48 
Cortical BMD 424.75±10.59 509.68±4.95 
 
Table 6.4-5: Weights of neonatal and 8 week old WT mice, sacrificed for comparison 
with GOAT-/- mice. 
Age Weights 
Female neonates-8 days 4.06±0.05 
Male neonates- 8 days 3.72±0.24 
Post-pregnant females 8 weeks 28.4±0.3 
Non-pregnant females 8 weeks 19.74±0.21 
 
 
Table 6.4-6: Limb lengths of WT neonates and post-pregnant female mice. 
Length (cm) 
Limb Right femur Right tibia Left femur Left tibia 
Female 
neonates 
0.58±0.02 0.86±0.02 0.58±0.02 0.89±0.03 
Male neonates 0.53±0.04 0.78±0.03 0.54±0.04 0.77±0.05 
8 wk post-
pregnant 
females 
1.47±0.18 1.75±0.05 1.55±0.05 1.75±0.05 
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